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ulcerative colitis
5.1. General
When deciding the appropriate treatment strategy for active
ulcerative colitis one should consider the activity, distribution
(proctitis, left-sided, extensive1), and pattern of disease. The
disease pattern includes relapse frequency, course of disease,
response to previous medications, side-effect profile of
medication and extra-intestinal manifestations. The age at
onset and disease duration may also be important factors.
5.1.1. Disease activity
The principal disease activity scoring systems used in
clinical trials are covered in Section 1.2 and have been
comprehensively reviewed.2 However there are some prac-
tical points that are relevant for routine clinical use. For
example, it is most important to distinguish patients with
severe ulcerative colitis necessitating hospital admission
from those with mild or moderately active disease who can
generally be managed as outpatients. The simplest, best
validated and most widely used index for identifying severe
UC remains that of Truelove and Witts3: any patient who has
a bloody stool frequency ≥6/day and a tachycardia
(N90 bpm), or temperature N37.8 °C, or anaemia
(haemoglobin b10.5 g/dL), or an elevated ESR (N30 mm/h)
has severe ulcerative colitis (Table 1.3). Only one additional
criterion in addition to the bloody stool frequency ≥6/day is
needed to define a severe attack.4,5
It should be standard practice to confirm the presence of
active colitis by sigmoidoscopy before starting treatment.
Flexible sigmoidoscopy and biopsy may exclude unexpected
causes of symptoms that mimic active disease such as
cytomegalovirus colitis, rectal mucosal prolapse, Crohn's
disease, malignancy, or even irritable bowel syndrome and
haemorrhoidal bleeding. There may be a significant overlap
between other diseases that mimic ulcerative colitis and the
broad spectrum of UC damage.6,7 In addition, all patients with
active disease require stool cultures with Clostridium difficile
toxin assay to exclude enteric infection. Patients with an
appropriate travel history should also have stool microscopy to
exclude parasitic infections such as amoebiasis.5.1.2. Approach
Patients should be encouraged to participate actively
in therapeutic decisions which should be tailored to the
individual.8 In a systematic review of clinical trials, 15% (95%
CI 10–21%) of patients entered remission when receivingplacebo,9 although placebo rates are lower if the endpoints
assessed are more stringent. However, prescribing no treat-
ment is rarely an option as rectal bleeding and urgency are
sufficiently concerning to the patient to justify topical therapy
even if no systemic therapy is recommended. Despite general
agreement that treatment decisions for active UC should be
based on the distribution, activity and pattern of disease,
numbers in clinical trials often become too small for statistically
valid conclusions to be drawn when patients are stratified
according to the distribution and pattern of disease. In addition,
it is important to remember that different preparations
containing the same active compound may have different
release profiles and may have either local or systemic activity.
Finally, the choice of therapeutic strategy should be influenced
by the balance between drug potency and side-effect profile;
previous response to treatment (especially when considering
treatment of a relapse, treatment of steroid-dependent or
-refractory disease, or immunomodulator-refractory disease);
and the presence of extraintestinal manifestations which may
require systemic therapy.5.2. Treatment according to site of disease and
disease activity
5.2.1. Proctitis
ECCO statement 5A
A mesalazine 1 g suppository once daily is the pre-
ferred initial treatment for mild or moderately active
proctitis [EL1b, RGA]. Mesalazine foam enemas are an
alternative [EL1b RG B]. Suppositories may deliver drug
more effectively to the rectum and are better
tolerated than enemas [EL3, RG C]. Combining topical
mesalazine with oral mesalazine or topical steroid is
more effective than either alone and should be
considered for escalation of treatment [EL1b, RG B].
Oral mesalazine alone is less effective [EL1b, RG B].
Refractory proctitis may require treatment with im-
munosuppressants and/or biologics [EL4, RG C]
The first line therapy for active colitis limited to the
rectum is topical mesalazine (5ASA). A Cochrane database
systematic review of 38 clinical trials of treatment of
procitis and left sided colitis confirmed the superiority of
this therapy over placebo for inducing symptomatic, endo-
scopic and histological improvement and remission.10 The
994 A. Dignass et al.pooled odds' ratio (POR) for symptomatic remission was 8.3
(8 trials, 95% CI 4.28 to 16.12; pb0.00001), for endoscopic
remission was 5.3 (7 trials, 95% CI 3.15 to 8.92; pb0.00001),
and for histologic remission was 6.3 (5 trials, 95% CI 2.74 to
14.40; pb0.0001). Suppositories are more appropriate than
enemas in patients with proctitis as they target the site of
inflammation (only 40% of foam enemas and 10% of liquid
enemas can be detected in the rectum after 4 h).11 There is
no dose response for topical therapy above a dose of 1 g
mesalazine daily. Once daily suppository therapy is as effective
as divided doses.12,13
Topical mesalazine is more effective than topical steroids,
whether assessing symptomatic remission (OR 2.42, 95% CI
1.72–3.41), endoscopic remission (OR 1.89, 95% CI 1.29–2.76),
or histological remission (OR 2.03, 95% CI 1.28–3.20).14 The
results of this meta-analysis were confirmed in the Cochrane
Database systematic review.8 Consequently topical steroids
should be reserved as second line therapy for patients who are
intolerant of topical mesalazine.15
Topical mesalazine is more effective than oral mesalazine
alone for proctitis.16 However, if using oral mesalazine
therapy alone, 3.6 g of a pH-dependent release profile pre-
paration was more effective than lower doses or placebo.17
The combination of oral and topical mesalazine appears to
be more effective than either alone in patients with disease
extending b50 cm from the anal verge.18 There have
been no trials on combination therapy for proctitis alone.
Combining topical mesalazine and topical steroid also helps:
beclomethasone dipropionate (3 mg) and mesalazine (2 g)
enemas produced significantly better clinical, endoscopic and
histological improvement than either agent alone.19 Patients
who fail to improve on oral/topical mesalazine and topical
corticosteroids should be treated with the addition of
oral prednisolone. The management of refractory proctitis is
discussed in Section 1.2.2.
5.2.2. Left sided colitis
ECCO Statement 5B
Left-sided active ulcerative colitis of mild–moderate
severity should initially be treated with an amino-
salicylate enema 1 g/day [EL1b, RG B] combined with
oral mesalazine N2 g/day [EL1a, RG A]. Topical therapy
with steroids or aminosalicylates alone [EL1b, RG B] as
well as mono-therapy with oral aminosalicylates [EL1a,
RG A] is less effective than oral plus topical 5ASA
therapy. Topical mesalazine is more effective than
topical steroid [EL1a, RG A]. Once daily dosing with
5ASA is as effective as divided doses [EL1b, RG A].
Systemic corticosteroids are appropriate if symptoms of
active colitis do not respond to mesalazine [EL1b, RG C].
Severe left-sided colitis is usually an indication for
hospital admission for intensive treatment with systemic
therapy [EL1b, RG B]
Although most therapeutic trials of mild to moderate active
colitis include patients with any disease distribution other than
proctitis, there is clear evidence that both oral and topical
mesalazine are effective for left-sided colitis compared toplacebo.10,20 First line therapy for mild to moderately active
left sided colitis is combined oral and topical mesalazine
therapy.15 This strategy has been investigated in a single trial
of 60 patients with distal colitis which demonstrated that
combined therapy wasmore effective andworkedmore rapidly
than either oral or topical therapy alone.18 Further support for
the use of combined oral and rectal mesalazine therapy in
patients with left sided colitis comes from an extrapolation of a
trial of combination therapy for extensive colitis.21 Further-
more, there is evidence that topical therapy achieves higher
rectal mucosal 5ASA concentrations than oral therapy22 and is
associated with improved clinical outcome.22,23
Mesalazine foam enemas are not inferior to liquid enemas
for inducing remission,24 so either are appropriate treat-
ments for left-sided colitis. Low volume enemas are not
inferior to high volume enemas in patients with left sided
colitis and may be better tolerated.25 Although several
meta-analyses have confirmed the superiority of rectal 5ASA
over rectal corticosteroids,10,14 a recentmeta-analysis of three
trials has suggested that rectal beclomethasone dipropionate is
equivalent to rectal 5ASA.26
Oral mesalazine has not been shown to be any more
effective than oral sulfasalazine (OR 0.83, 95% CI 0.60–1.13 for
clinical improvement or remission) but is better tolerated.27 An
initial systematic review of 9 placebo controlled trials of oral
aminosalicylates for active ulcerative colitis showed the overall
remission rate to be only 20%.28 However, additional placebo
controlled trials of a multimatrix mesalazine formulation for
mild–moderate UC,29,30 as well as a combined analysis31 have
since been published. These included 626 patients and showed
remission rates after 8 weeks of therapy of up to 40% with
evidence of mucosal healing in 32%. Importantly, these were
the first studies to demonstrate that once daily dosing is as
effective at inducing remission in mild to moderately active UC
as an equivalent total dose delivered twice daily.30 This finding
was confirmed in a double blind, double dummy randomised
non-inferiority trial of 3 g/day mesalazine granules delivered
either once daily or as 1 g three times daily.32 Indeed, in the
subgroup of 197 patients with left sided colitis, clinical
remission was more common at week 8 in the once daily
compared to the divided dose group (86% vs 73%; p=0.0298).
Therefore once daily dosing with mesalazine is preferred in
patients with left sided disease. The potential additional
benefit of combining once daily oral mesalazine with a
mesalazine enema has not been assessed in a clinical trial.
A meta-analysis of mesalazine for active UC confirms the
suggestion27,33 that there is a dose–response for mesalazine
with doses of≥2.0 g/day beingmore effective than b2.0 g/day
for the induction of remission (RR=0.91; 95% CI 0.85–0.98).20
The additional clinical benefit of doses greater than 2 g/day
was assessed in the ASCEND II trial in 268 patients with
moderately active disease, half of whom had distal disease.33
Responses to treatmentwere 71.8% in the 4.8 g group and 59.2%
in the 2.4 g group (p=0.036), although remission rates were
only 20.2% and 17.7% respectively (ns).33 Mucosal healing rates
at week 6 were higher in the 4.8 g/day group.34 The ASCEND III
trial confirmed the non-inferiority and safety of 4.8 g/day
mesalazine delivered as 800 mg tablets compared to 2.4 g/day
delivered as 400 mg tablets, in terms of achieving clinical
response at 6 weeks and also suggested a benefit of the higher
dose strategy for induction of remission (43% vs 35%; p=0.04).35
However, the MMX mesalazine trial showed no additional
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Therefore doses of at least 2 g mesalazine per day are
recommended.
The threshold for the introduction of oral steroids in patients
with mild to moderately active left sided colitis depends upon
the response to and tolerance of mesalazine, patient prefer-
ence and the physician's practice. The balance between desired
time to response and steroid-induced side effects should be
discussed with the patient. A guide to the expected time to
response for oral mesalazine can be taken from the pivotal
clinical trials (which included patients with extensive colitis as
well as left sided disease). In the ASCEND II trial themedian time
to cessation of rectal bleeding was 9 days in patients receiving
4.8 g mesalazine/day and 16 days in those receiving 2.4 g/
day.33 Likewise, the time to the first daywith no rectal bleeding
was 7 days for 4.8 g/day MMXmesalazine, although 37–45 days
therapy was required before sustained complete remission was
achieved.29,30 Combination oral and rectal mesalazine re-
duces the time to cessation of rectal bleeding compared to
oral therapy alone.21 Therefore, if a patient's symptoms
deteriorate, rectal bleeding persists beyond 10–14 days, or
sustained relief from all symptoms has not been achieved after
40 days of appropriatemesalazine therapy, additional therapy
should be commenced. This would normally involve the
addition of oral corticosteroids. There are, however, open
label data suggesting that a significant proportion of patients
who have not responded to 8 weeks' oral mesalazine may
enter clinical remission with a further 8 weeks of 4.8 g MMx
mesalazine irrespective of the initial dosing regieme.36
5.2.3. Extensive ulcerative colitis
ECCO Statement 5C
Extensive ulcerative colitis of mild–moderate severity
should initially be treated with oral 5-ASA N2 g/day
[EL1a, RG A], which should be combined with topical
mesalazine to increase remission rates if tolerated
[EL1b, RG A]. Once daily dosing with 5ASA is as
effective as divided doses [EL1b, RG A]. Systemic
corticosteroids are appropriate if symptoms of active
colitis do not respond to mesalazine [EL1b, RG C].
Severe extensive colitis is an indication for hospital
admission for intensive treatment [EL1b, RG B]
As the majority of clinical trials in mild to moderate
ulcerative colitis include patients with both pancolitis and left
sided colitis much of the evidence base for this statement is
discussed in Section 1.2.2. Oral mesalazine is clearly more
effective than placebo for the induction of remission of mild to
moderately active extensive ulcerative colitis.20,27,37 The
benefit of combining oral and rectal mesalazine was shown in
a trial of 116 patients randomised to oral mesalazine 4 g/day
with a 1 gmesalazine enema vs oral mesalazinewith a placebo
enema.21 Combined oral and rectal mesalazine achieved
clinical remission at week 8 in 64% compared to 43% on oral
mesalazine alone (p=0.03).21 Once daily mesalazine is as
effective as divided doses in patients with extensive coli-
tis.30,32 Failure of mild or moderately active disease to
respond to mesalazine is an indication to start oral prednis-
olone. Similarly, if a patient already on mesalazine N2 g/dayor immunomodulators as maintenance therapy has a relapse,
treatment with steroids is considered appropriate.
Evidence for the benefit of oral corticosteroids therapy
comes from two early studies of active UC which included
patients with extensive colitis. Oral prednisolone (starting at
40 mg daily combined with steroid enemas) induced remission
in 76% of 118 patients with mild to moderate disease within
2 weeks, compared to 52% treated with 8 g/day sulfasalazine
plus steroid enemas.38 Similar findings were reported by
Lennard-Jones,39 who found the combination of oral and rectal
steroids to be better than either alone. An appropriate regimen
for moderately active disease is prednisolone 40 mg/day for
1 week, reducing by 5 mg/day every week resulting in an
8 week course. Many different regimes are used, but it is
sensible to have a standard approach at any single centre, so
that steroid-dependence is recognised at an early stage and a
decision to start immunomodulators is facilitated. Shorter
courses (b3 weeks) are associated with early relapse and doses
of prednisolone≤15 mg day are ineffective for active disease.40
The efficacy of budesonide for active UCwas the subject of a
Cochrane database systematic review of 3 trials which
concluded that oral budesonide was significantly less likely to
induce clinical remission than oral mesalazine (RR 0.72, 95% CI
0.57 to 0.91) and had no benefit over placebo (RR 1.41, 95% CI
0.59 to 3.39).41 Therefore budesonide in its current formulation
is not recommended in routine clinical practice. Oral steroid
preparations with a colonic release mechanism and low
systemic bioavailability such as beclomethasone dipropionate
or budesonide are becoming available. One large study of 177
patients with active left-sided or extensive colitis reported that
beclomethasone dipropionate 5 mg/day had an effect similar to
that of 2.4 g mesalazine without systemic steroid
side-effects.42 A novel budesonide MMX preparation has
recently completed phase III trials at present with preliminary
data suggesting significant benefit over placebo for the
induction of remission in UC.43
5.2.4. Severe ulcerative colitis of any extent
Acute severe ulcerative colitis is a potentially life-
threatening condition. Historical prevalence data demon-
strate that 47/250 (18.8%) of initial disease flares are severe
and that 109/619 (17.6%) of all patients have a severe attack
as defined by criteria in Statement 1D at some stage in their
disease course.44 Understanding the implications of the
current medical and surgical strategies requires knowledge
of the historical context. In 1933, 16/21 (75%) patients died
within the first year after acute presentation with ulcerative
colitis45 and in 1950 a mortality of 22% was reported amongst
129 cases in the first year after diagnosis.46 The pivotal clinical
trial of steroid therapy for severe colitis in the 1950s reported
a mortality of 7% in those treated with corticosteroids
compared to 24% in the placebo group.3 The 2008 IBD audit
in the UK reported a mortality of 2.9% in patients admitted
with acute severe colitis, although it may be as low as b1% in
specialist centres.47 The response rate to appropriately dosed
intravenous steroids has not changed over the last 30 years.4
Therefore the reduction in mortality reported in the recent
series is likely to reflect improvements in the supportive care
of patients with severe UC and timely surgical intervention
when appropriate. Therefore, the Consensus participants
believe that all patients meeting the criteria for severe
colitis should be admitted to hospital for intensive treatment
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specialist Gastroenterologist and Colorectal surgeon.
ECCO Statement 5D
Patients with bloody diarrhoea ≥6/day and any signs of
systemic toxicity (tachycardia N90 bpm, fever N37.8 °C,
Hb b10.5 g/dL, or an ESR N30 mm/h) have severe
colitis and should be admitted to hospital for intensive
treatment [EL5, RG D]5.2.4.1. Therapeutic approach. All patients admitted with
severe colitis require appropriate investigations to confirm the
48diagnosis and exclude enteric infection. Intravenous cortico-
steroids remain the mainstay of conventional therapy.49 It is
essential to ensure that the therapeutic alternatives for rescue
of steroid-refractory disease (ciclosporin, tacrolimus, or
infliximab) are considered early (on or around day 3 of steroid
therapy) and that the decision making process is not delayed.
Patients remaining on ineffective medical therapy including
corticosteroids suffer a high morbidity associated with delayed
surgery.50,51 Therefore, the principal clinical dilemmas remain
how to identify at an early stage patients likely to require
colectomy, and when to start rescue medical therapy. The two
are not mutually exclusive and management demands careful
clinical judgement.
5.2.4.2. Conventional therapy.
Corticosteroids are generally given intravenously using methyl-
prednisolone 60 mg/24 h or hydrocortisone 100 mg four times
daily. Higher doses are no more effective, but lower doses are
less effective.4,52 Bolus injection is as effective as continuous
infusion.53 Treatment should be given for a defined period as
extending therapy beyond 7 to 10 days carries no additional
benefit.4 A systematic review of 32 trials of steroid therapy for
acute severe colitis involving 1991 patients from 1974 to 2006
reported an overall response to steroids (intravenous hydrocor-
tisone, methylprednisolone, or betamethasone) of 67% (95% CI
65–69%).4 Out of the 1991 patients, 565 (29%, 95% CI 28–31%)
came to colectomy.Mortality was 1% (22/1991, 95% CI 0.7–1.6%)
and none of these outcomes changed between 1974 and 2006
(R2=0.07, p=0.8). Because of substantial heterogeneity, it was
not possible to discriminate between complete and partial
responses to steroids.
One small randomised clinical trial demonstrated that
ciclosporin monotherapy (ciclosporin, 4 mg/kg/day intrave-
nously) was as effective as intravenous methylprednisolone
40 mg/day for acute severe colitis. A clinical response was
reported in 10/15 ciclosporin patients versus 8/15 steroid
patients.54 Furthermore, half of all patients in another
study comparing low dose with high dose ciclosporin55 also
received ciclosporin monotherapy, without concomitant intra-
venous steroids. Consequently monotherapy with ciclosporin
(normally at 2 mg/kg/day) is a useful option in those patients
with severe colitis when steroids are best avoided, such as
those susceptible to steroid-psychosis, patients with concom-
itant osteoporosis or those with poorly controlled diabetes.
Other measures that are considered appropriate in
addition to intravenous steroids include:
• Intravenous fluid and electrolyte replacement to correct and
prevent dehydration or electrolyte imbalance. Potassiumsupplementation of at least 60 mmol/day is almost invariably
necessary. Hypokalaemia or hypomagnesaemia can promote
toxic dilatation.56
• Unprepared limited flexible sigmoidoscopy and biopsy to
confirm the diagnosis and exclude cytomegalovirus infec-
tion57,58 which is often associated with a steroid refractory
disease course59 and requires appropriate treatment.60
• Stool cultures and assay for co-existing Clostridium difficile
toxin, which is becoming more prevalent in patients admitted
with severe colitis and is associated with increased morbidity,
mortality and health care costs.61–64 If detected appropriate
antibiotic therapy should be administered. Consideration
should be given to stopping immunosuppressive therapy where
possible,65 although this may not always be appropriate.60
• Subcutaneous prophylactic low molecular weight heparin to
reduce the risk of thromboembolism which has been shown
to be increased in patients with IBD compared to controls,
especially during a disease flare and is not related to other
thromboembolic risk factors.66,67
• Nutritional support if the patient is malnourished. Enteral
nutrition is most appropriate and associated with signifi-
cantly fewer complications than parenteral nutrition in
acute colitis (9% vs 35%).68 Bowel rest through intravenous
nutrition does not alter the outcome.69
• Withdrawal of anticholinergic, antidiarrhoeal, NSAID and
opioid drugs, which may risk precipitating colonic dilata-
tion.56,70,71
• Topical therapy (corticosteroids or mesalazine) if tolerated
and retained, although there have been no systematic
studies in acute severe colitis.49
• Antibiotics only if infection is considered (such as in an
acute, first attack of short duration, after recent admission
to hospital or after travel to an area where amoebiasis is
endemic), or immediately prior to surgery. Controlled trials
of oral or intravenous metronidazole, tobramycin, cipro-
floxacin or vancomycin in acute colitis have shown no
consistent benefit in addition to conventional therapy.72–74
• Blood transfusion to maintain a haemoglobin above 8–
10 g/dL.
• A multidisciplinary approach between the gastroenterologists
and colorectal surgeons looking after the patient is essential.
5.2.5. Intravenous-steroid refractory ulcerative colitis of
any extent
ECCO Statement 5E
The response to intravenous steroids is best assessed
objectively around the third day [EL2b, RGB]. Treatment
options including colectomy should be discussed with
patients with severely active UC not responding to
intravenous steroids. Second line therapy with either
ciclosporin [EL1b, RG B], or infliximab [EL1b, RG B] or
tacrolimus [EL4, RG C] may be appropriate. If there is no
improvement within 4–7 days of salvage therapy,
colectomy is recommended [EL4, RG C]. Third line
medical therapy may be considered at a specialist centre
[EL4, RG C]The timing of colectomy for severe colitis remains one of
the most difficult decisions that a gastroenterologist has to
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therapies for patients with severe colitis refractory to
intravenous steroids have been published. However, it
is important that physicians do not acquiesce with the
patient's understandable desire to delay surgery with inap-
propriate or unduly prolonged courses of therapy as this will
increase the morbidity and mortality associated with subse-
quent surgery.50,51 Therefore, the important issues that must
be considered and discussed with the patient include:
1) Can one predict who will fail to respond to iv corticoste-
roids early, so that appropriate salvage therapy can be
started in a timely fashion?
2) Are the available salvage therapies (calcineurin inhibitors
or infliximab) equally effective? Are there subgroups of
patients in whom one strategy is preferred over another?
3) When should the response to salvage therapy be
assessed, and if a patient fails to respond to one salvage
therapy should a second therapy be commenced?
Simple, objective measures are needed to aid decision-
making. Factors that predict the need for colectomy in acute
severe colitis can broadly be divided into clinical, biochemical
and radiological markers. Several scoring systems in clinical
practice use a combination of clinical and biochemical
markers5 (for a review, see75). Genetic polymorphisms have
the potential to predict the outcome of disease in an individual
from the time of diagnosis,76,77 but they cannot be used for
decision-making when colectomy is imminent. In addition to
triggering a decision to commence salvage therapy, meeting
the criteria for steroid failure with one of these predictive
indices should mandate surgical consultation and assessment
by a stomatherapist, if this has not already occurred.
• Clinical markers depend onmeasures such as stool frequency
or pyrexia. A stool frequency N12/day on day 2 of iv
corticosteroids was associated with rate of colectomy of
55%,78 whilst a frequency N8/day or a stool frequency
between three and eight together with a CRP N45 mg/L on
day 3 predicted colectomy in 85% on that admission: the
Oxford Criteria.5 Similarly a stool frequency ×0.14 CRP being
≥8 on day 3 predicted colectomy in 75%: the Sweden Index.79
• Biochemicalmarkers include a high CRP, lowalbumin and pH.
An ESR N75 or a pyrexia N38 °C on admission was associated
with a 5–9-fold increase in the need for colectomy in a
prospective study of 67 patients.80 In this study, lack of
response to steroids was predicted by b40% reduction in stool
frequency within 5 days. Nevertheless, patients (and their
doctors) prefer to know an absolute estimate of the
likelihood of colectomy, rather than relative measures.
• Radiological/endoscopic criteria include the presence of
colonic dilatation N5.5 cm (associated with a 75% need for
colectomy), or mucosal islands on a plain abdominal
radiograph (75% colectomy).78 A retrospective study
reported that the presence of an ileus (indicated by 3 or
more small bowel loops of gas) was associated with
colectomy in 73% patients.81 The depth of colonic ulcera-
tion after gentle air insufflation identified 42/49 patients
with deep ulcers that were associated with the need for
colectomy,82 but this is not widely used in clinical practice.
Endoscopic appearances at admission may also predict the
need for colonoscopy (although patients with severe colitisshould not undergo complete colonoscopy due to the
increased risk of perforation). Thus 43/46 (93%) patients
with severe ulceration went onto have colectomy compared
to 10/39 (26%) of those without such lesions.83 A retrospec-
tive study of 167 patients in whom a high proportion (40%)
came to colectomy, developed a numerical score combining
mean stool frequency over 3 days, presence or absence of
colonic dilatation and hypoalbuminaemia (b30 g/L) on
admission that was associated with the need for colectomy
in up to 85%.84
5.2.5.1. Ciclosporin. Two placebo controlled trials have
confirmed the efficacy of ciclosporin in the treatment of
severe UC.54,85 The study by Lichtiger included only patients
who had failed iv corticosteroids.85 Nine of 11 patients failing
steroids improved on 4 mg/kg/day iv ciclosporin, whilst all 9
on placebo failed to improve (RR 0.18, 95% CI 0.05–0.64). In a
further trial, 73 patients were randomised to either 2 mg/kg
or 4 mg/kg of intravenous ciclosporin.55 Response rates at
8 days were similar in both groups (83% and 82% respectively),
with 9% coming to colectomy in the 2 mg/kg group and 13% in
the 4 mg/kg group. Although not all patients were failing
iv corticosteroids at entry, 2 mg/kg/day has become the
standard dose used in current clinical practice. Pooling results
from controlled and non controlled clinical trials, between
76% and 85% of patients will respond to iv ciclosporin and
avoid colectomy in the short term.54,55,85–87 These suggest
a median time to response of 4 days which allows timely
colectomy in non responders.55 However, the narrow
therapeutic index of ciclosporin and its side-effect profile
(including mortality rates of 3–4%) have limited accept-
ability, such that in the 2008 UK National IBD audit only 24%
of patients admitted with steroid-refractory severe UC
received ciclosporin. A Cochrane review88 concluded that
numbers in controlled trials were so few that there was
limited evidence for ciclosporin being more effective than
standard treatment alone for severe UC.
Reluctance to use ciclosporin in this patient group
may also reflect concerns about its ability to prevent
colectomy in the longer term. In two series, 58% of 76
patients89 and 88% of 142 patients87 came to colectomy over
7 years. A single centre review of the long term outcome of
71 patients treated with iv ciclosporin for severe colitis
reported that successful transition to an oral thiopurine was a
significant factor in preventing future colectomy (OR 0.01, 95%
CI 0.001–0.09, pb0.0001).90 Successful transition to thiopurine
therapy and being thiopurine-naïve at baseline have been
confirmed as factors that reduce the risk of long term
colectomy in this patient group.87,91,92 Patients that have UC
refractory to adequate thiopurine therapy may therefore be
less suitable candidates for ciclosporin rescue therapy.
5.2.5.2. Tacrolimus. Tacrolimus is a calcineurin inhibitor
that acts via amechanism similar to ciclosporin (Section 5.4.7).
One randomised placebo controlled trial of two tacrolimus
dosing strategies has shown significant benefit over placebo in
patients with UC.93 This included 27/60 patients with severe
colitis. No patient entered complete remission in any group. A
partial responsewas seen in 67% (4/6) of patients on tacrolimus
adjusted to trough levels of 10–15 ng/mL, 50% (5/10) of
patients on tacrolimus adjusted to trough levels of 5–10 ng/mL
and 18% (2/11) of patients on placebo (p=ns). This study was
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with severe colitis. However, case series have shown broadly
similar results to ciclosporin after both intravenous (0.01 to
0.02 mg/kg) and oral (0.1 to 0.2 mg/kg) administration.94–96
The long term cumulative colectomy free survival in patients
with UC treated with tacrolimus has been reported to be 57%
at 44 months, although this included a very heterogeneous
population.97
5.2.5.3. Infliximab. Infliximab as a single dose (5 mg/kg)
has also been shown to be an effective salvage therapy in
patients with severe UC refractory to iv steroids. A pivotal,
but small randomised controlled study included 45 patients
(24 infliximab and 21 placebo) who were all initially treated
with iv betamethasone.98 Colectomy rates at 3 months were
significantly lower in patients receiving infliximab than
placebo (7/24 vs 14/21: p=0.017; OR 4.9, 95% CI 1.4–17).
Two different scores were used to identify patients before
randomization to infliximab or placebo. Patients with less
active disease who were randomised after 5–7 days of iv
steroids seemed to benefit more than patients with more
severe disease randomised at day 3. An earlier pilot study and
retrospective review of infliximab for acute severe colitis
refractory to steroids have shown variable results.99,100 Long
term follow up of patients in the placebo controlled trial
revealed a colectomy rate at 3 years of 12/24 (50%) patients
given infliximab and 16/21 (76%) given placebo (p=0.012),
although use of thiopurine therapy was not controlled and
differed between groups.101 Case series report 20%, 33%, 57%
or 75% colectomy rates after infliximab for iv steroid-refractory
UC.100,102–104
Few studies have assessed predictors of response to
infliximab in patients with severe corticosteroid refractory
disease. A study which included patients with both moderate
and severe disease reported increased short term response
in patients with a high disease activity at baseline and
patients who were seronegative for ANCA or were homozy-
gous for the IBD risk increasing variants in the IL23R gene.105
A retrospective study of 83 Italian patients suggests that
patients receiving a single infusion are more likely to require
colectomy at 2 months than those who receive 2 or more
infusions (9/26 compared to 3/57; p=0.001, OR=9.53).106
5.2.5.4. Selection between calcineurin inhibitors and
infliximab. A retrospective review of two cohorts of
patients receiving salvage therapy for steroid-refractory
severe UC (49 treated with infliximab and 43 with ciclosporin)
suggests a lower immediate colectomy rate in the ciclosporin
group.107 After adjusting for potential confounding factors,
Cox regression analysis yielded adjusted hazard ratios for risk
of colectomy in infliximab-treated patients of 11.2 (95% CI
2.4–53.1, p=0.002) at 3 months and of 3.0 (95% CI 1.1–8.2,
p=0.030) at 12 months in comparison with ciclosporin-treated
patients. In contrast, the open label CYSIF trial randomised
111 thiopurine-naive patients with severe colitis (Lichtiger
scoreN10) despite 5 days of iv steroids to iv ciclosporin
2 mg/kg/day for 8 days (levels 150–250 ng/mL) followed by
4 mg/kg/day oral therapy, or infliximab 5 mg/kg at weeks
0, 2 and 6.108 All responders at day 7 received oral
azathioprine and tapered steroids from day 8. The trial
was initially powered to demonstrate less treatment failure
with ciclosporin than infliximab between days 7 and 98 (lack ofresponse at day 7, relapse between day 7 and 98, lack of
steroid free remission at day 98, colectomy or treatment
interruption before day 98). Approximately 85% of patients
in both groups responded to treatment by day 7. Treat-
ment failure at day 98 (the primary endpoint) was reported
in 60% of patients in the ciclosporin arm compared to 54%
of patients in the infliximab arm (treatment difference
6.4% 95% CI −12 to 24.8%; p=0.49). The colectomy rates by
day 98 in the ciclosporin versus the infliximab groups were
18% and 21% respectively (p=0.66).108 Serious adverse
events were numerically more common in the infliximab
group (17/56, vs 9/55 on ciclosporin), with 9 serious infections
in total within the 98 day study, but the differences did not
reach significance. One patient who received ciclosporin
died of a myocardial infarct. A large UK based pragmatic
clinical trial (CONSTRUCT) using quality of life and health
economic endpoints is still recruiting (2012). Thus at
present there are no randomised trials comparing the two
drugs that show clear advantages of one strategy over the
other.
Therefore, in the absence of an absolute or relative
contra-indication to a particular strategy, the individual
circumstances of each patient should be considered when
deciding between options for salvage therapy. Intravenous
ciclosporin should be avoided in patients with low choles-
terol or magnesium in view of the increased incidence of
neurological side effects in this patient group. If a patient
has acute severe colitis despite existing treatment with an
immunomodulator at an appropriate dose and duration, it is
important to consider whether there are options for long
term maintenance of remission. The long term benefit of
infliximab as maintenance therapy in these circumstances
has not been tested in a controlled trial, because these
patients are a different population to those recruited to the
ACT 1 and 2 trials.109 In this situation, the risks, as well as
the potential benefit, of deferring (or even avoiding)
colectomy need careful discussion with individual patients.
Many gastroenterologists will be more familiar with the
adverse-event profile of infliximab compared to ciclosporin
or tacrolimus. However, the short half life of ciclosporin
gives it a potential advantage over infliximab. In the event
that salvage therapy fails and colectomy is required, ciclo-
sporin will clear from the circulation far quicker than
infliximab. This may have advantages given that septic com-
plications are the major cause of post-operative morbidity
and mortality.100 However, prolonged use of corticosteroids
appears to remain the main risk factor for post-operative
complications after colectomy.110 One small series reported
that ciclosporin did not increase the risk of complications
after colectomy.111 In contrast, there is ongoing debate as to
whether infliximab increases the risk of surgical com-
plications112–115 and no data are available that relate only to
emergency colectomy for patients with acute severe UC (see
Section 7.6.3, Statement 7V).
5.2.5.5. Third line medical therapy. In general only a
single attempt at rescue therapy with a calcineurin inhibitor
or infliximab should be considered before referral for
colectomy. However, treatment success has been reported
for sequential use of calcineurin inhibitors and infliximab
after iv corticosteroids. The initial reports of patients
receiving ciclosporin after infliximab or vice versa for
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morbidity and mortality.116 However, a more recent cohort
from France assessed outcome after third line medical
therapy in 86 patients, the majority of whom received
ciclosporin followed by infliximab.117 The probability of
colectomy-free survival (±s.e.) was 61.3±5.3% at 3 months
and 41.3±5.6% at 12 months, although clinical remission was
achieved in only 30% and three year colectomy rates were 63%.
Remission has been reported in 25%–50% of patients receiving
infliximab for severe UC refractory to tacrolimus although not
all these patients were hospitalised.118,119 Therefore, in
highly selected cases, after careful discussion between the
patient, gastroenterologist and colorectal surgeon, third line
medical therapy can be considered in a specialist referral
centre.
5.2.6. Toxic dilatation and complications of severe
ulcerative colitis
5.2.6.1. Toxic megacolon. Toxic dilatation (megacolon) is
defined as total or segmental non-obstructive dilatation of
the colon ≥5.5 cm associated with systemic toxicity.56
Although its true incidence has not been reported, approx-
imately 5% of patients with acute, severe colitis admitted to
hospital will have toxic dilatation.56 Risk factors include
hypokalaemia, hypomagnesaemia, bowel preparation, and
the use of anti-diarrhoeal therapy.56 Earlier diagnosis of
severe colitis, more intensive medical management and
earlier surgery have reduced the incidence and mortality
of toxic megacolon complicating UC. In addition to iv
hydrocortisone, empirical treatment with oral vancomy-
cin should be considered until stool is confirmed negative
for Clostridium difficile toxin. Nasogastric suction cannot
be expected to decompress the colon and is unnecessary.
The classic knee–elbow position may relieve disten-
sion,120 but is generally impracticable. An opinion from
an experienced colorectal surgeon is required on the day
of admission. It should be made clear to all that there is a
limited window of opportunity for medical treatment to
work and that if there is no improvement early colectomy
will be necessary.
5.2.6.2. Perforation, haemorrhage and others. Perforation
is the most serious complication of acute severe colitis and is
often associated with inappropriate total colonoscopy or toxic
dilatation where colectomy has been inappropriately delayed.
It carries a mortality of up to 50%.56 Other complications
includemassive haemorrhage, and thromboembolism including
cerebral sinus thrombosis.66,67
5.2.6.3. Long term outcome of severe colitis. There is
evidence that achieving complete clinical remission on the
index hospital admission improves long term outcome and
delays the need for colectomy.121 As mentioned above,
patients needing ciclosporin for acute severe colitis who are
naïve to immunomodulator therapy and successfully transition
to thiopurine maintenance therapy are less likely to require
colectomy in long term follow‐up.87,90,91 Perhaps unsurpris-
ingly, irrespective of whether ciclosporin or infliximab is used
as salvage therapy, patients with clinical, biochemical or
endoscopic evidence of more severe disease at presentation
are more likely to require colectomy.122 Data on the burden ofmedical and surgical treatment of severe colitis and attendant
complications, related to patient-orientated outcomes
(hospitalisation, time off work, colectomy and mortality) are
still required.
5.2.7. Refractory proctitis and distal colitisRefractory proctitis and distal colitis present common
clinical dilemmas (review in123). There are few appropriate-
ly controlled rigorous clinical trials in this specific popula-
tion, but a coherent therapeutic strategy is needed if
patients are not to get frustrated by persistent symptoms.
It is clearly important to consider and identify the aetiology
of the refractory disease course. One obvious explanation is
that the disease is refractory to medication being pre-
scribed. However, alternative explanations include:
1) Poor adherence to prescribed therapy
2) Delivery of an inadequate concentration of the active drug to the
inflamed mucosa
3) Unrecognised complications (such as proximal constipation or
infection)
4) Inappropriate diagnosis (such as co-existent irritable bowel
syndrome, Crohn's disease, mucosal prolapse, or cancer).
Therefore, the initial step is to review current symptoms
and treatment to date, with a careful discussion about
adherence. This should be followed by reassessment of the
diagnosis by stool culture, endoscopy and biopsy. The next
step is to ensure that conventional therapy (Sections 5.2.1
and 5.2.2) has been used appropriately. Attention in
particular should be paid to the formulation of topical
therapy and whether it was used in conjunction with an
adequate dose of oral therapy. An abdominal X-ray can be
useful to diagnose proximal constipation, since abnormal
intestinal motility induces proximal colonic stasis in pa-
tients with distal colitis which may affect drug delivery.124
If there is visible faecal loading, a laxative should be
considered.
Patients with endoscopically documented active colitis
who fail oral corticosteroids combined with oral and rectal
5ASA therapy have refractory proctitis or distal colitis.
Therapeutic options include admission for intravenous
steroid therapy which has been reported to induce remission
in a high proportion of patients.125 Alternatively, there is
open label evidence, often from retrospective case reviews,
supporting the use of salvage medical therapies such as
oral or rectal ciclosporin, oral or rectal tacrolimus, or
infliximab.126–129
If disease persists in spite of these approaches, surgery is
likely to be the outcome, but if the patient is not acutely ill
then the decision should never precipitate and a range of
topical or anecdotal therapies are available. Placebo
controlled trials have suggested a benefit of short chain
fatty acid enemas,130,131 although difficulties with produc-
tion and availability limit their widespread use. Historical
small open label trials have suggested benefit from alterna-
tive topical therapies such as lidocaine enemas, acetarsol
(arsenic) suppositories, Epidermal Growth Factor enemas,
and transdermal nicotine patches.132–135 The choice de-
pends on local availability and personal preference, since
many have to be made up individually by pharmacy
(reviewed in136). There is evidence from retrospective
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in patients with refractory proctitis.137 Clinical judgement
and an honest appraisal about the impact of symptoms on
the quality of life or employment are necessary. Up to 10% of
patients who have a colectomy for refractory UC only have
distal disease. The outcome of colectomy and pouch
formation for distal colitis is usually good. In 263 patients
who had a restorative proctocolectomy at one French centre
(1986–96), 27 had surgery for distal disease.138 There was a
significant decrease in daytime and nocturnal stool frequency
after surgery and previously undiagnosed severe dysplasia was
identified in 2 patients. All but one patient were satisfied with
the results and 25/27 wished that they had had surgery
sooner.
5.3. Treatment according to the course or
behaviour of disease
Treatment decisions may differ between patients at initial
presentation and subsequent relapse, depending on the
pattern of relapse and previous response to therapy. Some
patients have refractory disease that remains active in
spite of prescribed treatment, others relapse when therapy
such as corticosteroids are tapered (steroid dependent).
Treatment decisions should also be influenced by clinical
factors that predict adverse treatment outcomes including
colectomy. In outpatients with active ulcerative colitis
factors associated with an increased risk of colectomy
include: steroid-dependent disease course, serum CRP levels
≥20 mg/L, high clinical disease activity, and moderate to
severe UC with a disease duration ≤3 years.139 Lack of
mucosal healing at one year after treatment is another risk
factor for future colectomy.140
5.3.1. Treatment of relapse compared to new cases
The initial treatment of relapse may include the treat-
ment that worked for the previous disease flare, although
maintenance therapy should also be optimised. Other
factors to consider include patient opinion (adverse effects,
necessary speed of response, convenience, etc.), timing of
relapse, concurrent therapy (whether a relapse occurred
during treatment with immunomodulators) and adherence to
maintenance therapy.
5.3.2. Early relapse
Patients who have an early (b3 months) relapse require
further induction therapy, but should also commence aza-
thioprine or mercaptopurine to reduce the risk of a sub-
sequent relapse. Opinion is divided whether to use the same
induction treatment as before to achieve remission or to
use more potent therapy. It is generally unnecessary to re-
evaluate the distribution of disease unless this will influence
medical or surgical management. Continued medical thera-
py that does not achieve steroid-free remission is not
recommended.
5.3.3. ‘Steroid-dependent’, active ulcerative colitis
ECCO Statement 5F
Patients with steroid-dependent disease should be treat-
ed with azathioprine/mercaptopurine [EL1b, RG B]Azathioprine is significantly more effective than
mesalazine at achieving clinical and endoscopic remission
in the treatment of steroid-dependent UC. 72 patients
were randomised to receive azathioprine 2 mg/kg/day or
oral mesalazine 3.2 g/day, in addition to prednisolone
40 mg/day.141 This demonstrated that 53% on azathioprine
achieved steroid-free clinical and endoscopic remission after
6 months compared to 21% on mesalazine (OR 4.78, 95% CI
1.57–14.5). In addition, an open label observational cohort
study in 42 steroid dependent patients reported steroid-free
remission with azathioprine at 12, 24, and 36 months of 55%,
52%, and 45%, respectively.142 Therefore thiopurines should
be the first choice of therapy for patients who flare when
steroids are withdrawn. Patients with active disease despite
steroid therapy require appropriate induction therapy
(Section 5.3.4), including consideration of anti-TNF therapy
(adalimumab or infliximab).
5.3.4. Oral steroid-refractory ulcerative colitis
Statement 5G
Outpatients with moderately active steroid refractory
disease should be treated with anti TNF therapy [EL1b,
RG B] or tacrolimus [EL2b, RG C], although surgical
options or admission for parenteral steroid therapy
could also be considered [EL5 RG D]For active UC that is refractory to steroids, other causes
of persistent symptoms including coexistent cytomegalovi-
rus, Clostridium difficile or cancer should be considered.
If active steroid-refractory UC is confirmed, alternative
therapy to induce steroid-free remission is required.
Anti-TNF therapy has clear evidence of benefit in this
patient group. The ACT 1 and 2 studies included 408/728
(56%) patients taking oral steroids at study entry,109
although their dose of steroids may have been sub-optimal.
At 30 weeks, significantly more of these patients receiving
scheduled infliximab than placebo achieved steroid free
remission (28/130 (21%) vs 10/139 (7%); p=0.01); at one
year (ACT 1 alone), the figures were 26% and 9% respec-
tively (p=0.006). The recently presented UC-SUCCESS
trial suggests that steroid-refractory patients with mod-
erately active UC who are naïve to immunomodulator
therapy are significantly more likely to enter steroid-free
remission after 16 weeks if they receive a combination
of azathioprine and infliximab (induction and maintenance
therapy) than either agent alone.143 This double-blind
placebo-controlled trial reported that steroid free
remission at week 16 was achieved in 24% of the 70
patients receiving azathioprine monotherapy, 22% of 77
patients given infliximab monotherapy and 40% of 78
patients receiving infliximab and azathioprine combina-
tion therapy (p=0.032 for combination vs azathioprine
monotherapy and p=0.017 for combination vs infliximab
monotherapy).
Adalimumab has also shown benefit over placebo
for the induction of remission in 390 outpatients with
moderately active UC.144 Patients randomised to re-
ceive 160 mg/80 mg/40 mg every other week (eow) were
1001Second European Consensus on the diagnosis and management of ulcerative colitissignificantly more likely to achieve remission at week 8 than
those receiving placebo (18.5% compared to 9.2%; p=0.031).
Remission rates at week 8 for patients who were on steroids at
baseline in the adalimumab 160 mg/80 mg/40 mg eow com-
pared to placebo groups were 12/71 (16.9%) and 8/89 (9%)
respectively. In a separate randomised placebo-controlled
trial of adalimumab for induction and maintenance of
remission, which included patients with prior infliximab
exposure, the sub group of patients on corticosteroids at
baseline was significantly more likely to be in steroid free
remission at week 52 if treated with 160 mg/80 mg/40 mg
eow than placebo (13.3% vs 5.7%, p=0.035).144 Adalimumab is
now licenced (2012) for the treatment ofmoderate or severely
active UC in Europe.
A single placebo-controlled trial of tacrolimus at two
different dosing strategies compared to placebo in 65
patients included 60 patients with moderate or severely
active disease despite concomitant steroid therapy, of
whom 15 patients were refractory to at least 30 mg oral
prednisolone for 2 weeks.93 Although patients were
hospitalised in this study, they did not all meet the criteria
for severe steroid-unresponsive UC used in Section 1.2.5. No
patient with steroid-refractory disease at baseline entered
complete remission at week 2 in any group. However partial
response was seen in 13/19 (68%) patients randomised to
receive tacrolimus adjusted to trough levels of 10–15 ng/mL,
8/21 (38%) patients randomised to receive tacrolimus
adjusted to trough levels 5–10 ng/mL and 2/20 (10%)
patients on placebo (pb0.01 for high trough compared to
placebo). After a further 8 week open-label therapy, there
was a significant reduction in the mean daily dose of
prednisolone, although the exact numbers of patients in
each group able to withdraw from steroids completely is not
reported. A subsequent Cochrane database systematic
review which included this trial alone, concluded that
caution should be used in interpreting the data due to
inadequacies in study design and the small number of patients
included.145
It should be noted that none of the treatments discussed
above have achieved steroid-free remission at any time
point in the majority of patients. Therefore the expectations
of the patient (and the physician) have to be managed and
thought given to admission for intravenous steroid therapy,
as well as semi-elective colectomy. The patient's gender,
age, fecundity and extent of disease should be taken into
account. The sequence (or hierarchy) of therapy has to
depend on the individual circumstances and acceptability to
the patient.5.3.5. Immunomodulator-refractory ulcerative colitis
ECCO Statement 5H
Patients with moderately active ulcerative colitis
refractory to thiopurines should be treated with anti
TNF therapy [EL1b, RG B] or tacrolimus [EL4, RG C]
although colectomy should also be considered. Continued
medical therapy that does not achieve a clear clinical
benefit is not recommended [EL5, RG D]Immunomodulator-refractory disease is also best reas-
sessed by endoscopy and biopsy to confirm the diagnosis and
exclude complications. A therapeutic strategy that includes
consideration of how steroid-free remission will be achieved
and maintained should be discussed with the patient. In the
absence of contraindications, anti TNF therapy should be
considered (Section 5.4.3). There is case series evidence to
support the use of tacrolimus,146,147 but no controlled
clinical trial has included this patient group. Careful
discussion with the patients is required as to the relative
risks and benefits of immunosuppressive therapy compared
to colectomy, which may be a more appropriate option for
some patients.
The ACT 1 and ACT 2 trials included 334/728 (46%)
patients with active disease refractory to immunomodulator
therapy.109 Infliximab at either dose used (5 mg/kg or
10 mg/kg) achieved clinical remission in a significantly
greater proportion of patients at week 8 than placebo,
although the exact response rate for the subgroup of
immunomodulator-refractory patients was not reported. A
Cochrane database systematic review of the efficacy of 7
trials of infliximab for treating patients with moderate to
severe UC refractory to corticosteroids and/or immuno-
modulators concluded that infliximab (three intravenous
infusions at 0, 2, and 6 weeks) was more effective than
placebo in inducing clinical remission at week 8 (RR 3.22,
95% CI 2.18–4.76).148 Again, this review did not report the
benefit in the subgroup of patients refractory to immuno-
modulator therapy.
In the trial demonstrating the superiority of adalimumab
over placebo for the induction of remission of UC discussed in
Section 1.3.4, 155 of the 390 (39.7%) patients were on con-
comitant immunosuppression at baseline.144,149 Adalimumab
160 mg/80 mg/40 mg eow induced clinical remission at week
8 in 8/53 (15.1%) patients compared to 2/52 patients receiving
placebo (3.8%). A prospective single centre cohort study of
53 patients receiving either infliximab or adalimumab for
moderately active UC reported short term clinical response in
88.7% patients with no significant difference in the response
rates between drugs.150 All patients recruited had failed or
were intolerant to immunomodulator therapy although only
5/25 patients treated with adalimumab and 15/28 patients
treated with infliximab were on concomitant immunomodu-
lator therapy at baseline.
5.4. Therapy-specific considerations
The therapeutic goal should be to induce steroid-free
clinical remission, but it is essential to keep in mind how
remission will be maintained (Section 6). The treatment
strategy depends primarily on the activity and distribution of
UC (Section 1.2); the current section considers drug-specific
aspects of treatment not addressed in that section.
5.4.1. Aminosalicylates for active UC
5.4.1.1. Efficacy of aminosalicylates. There is much dis-
cussion of how different delivery systems may influence
response, but evidence from appropriately designed compar-
ative trials is scarce. Delivery systems can be divided into
azo-compounds, controlled release, pH-dependent (either
pH6 or pH7) and composite (pH-dependent combined with
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concur that oral aminosalicylates are effective for treating
active UC.20,27,28,37 The most recent systematic review quotes
a relative risk of no remission with 5-ASA compared to placebo
of 0.79 (95% CI 0.73–0.85; NNT=6).20 Available data do not
suggest a difference in efficacy between any of the 5-ASA
preparations for active UC. As discussed in Section 1.2.2, doses
of ≥2.0 g/day are more effective than b2.0 g/day for
remission (RR=0.91; 95% CI 0.85–0.98).20 Several trials have
reported that once daily dosing is as effective as divided doses
for the induction of remission.30,32,151,152
Mesalazine has been shown to be as effective as
sulfasalazine for inducing response or remission in 2 separate
meta-analyses, and is better tolerated27153. There have
been few clinical trials comparing the efficacy of newer
aminosalicylates for inducing remission. In 2 of 3 trials of
balsalazide versus mesalazine, results for defined primary
and secondary endpoints failed to demonstrate statistically
significant differences,154–156 although a more recent
meta-analysis reports a slight but statistically significant
advantage.157 Another study compared Ipocol, a pH7-
dependent release mesalazine, with Asacol and found no
significant difference in remission rates after 2.4 g/days
for 8 weeks,158 although insufficiently powered for a non-
inferiority design. It is important to remember that many
of the placebo-controlled trials demonstrating efficacy for
different mesalazine preparation have used different
definitions of remission. This is important as it is not
possible to compare the remission rates reported between
trials to determine relative efficacy. Indeed when the
clinical outcome data from the ASCEND I/II trials were
re-analysed using the different definitions of remission
from other 5ASA trials, the rate of remission reported
varies from 22% to 50%.159 It is clear that the more
stringent the definition of remission used, the more likely
it is that the patient will maintain that remission during
follow up. Proprietary prescribing of mesalazine has been
recommended,160 but for active UC the choice of 5ASA
cannot be made on the grounds of efficacy alone. The route
of delivery, dose frequency, cost and availability are more
relevant factors in the choice.
5.4.1.2. Adverse effects of aminosalicylates. Mesalazine
has a topical action on colonic epithelial cells, where it is also
metabolised. Systemic exposure is therefore unnecessary.
This means that drug efficacy cannot be deduced from
pharmacokinetic comparisons, although absorption might
conceivably influence adverse events. Mesalazine intolerance
occurs in up to 15%. Diarrhoea (3%), headache (2%), nausea
(2%), rash (1%) and thrombocytopenia (b1%) are reported,
but a systematic review has confirmed that all new 5-ASA
agents are safe, with adverse events that are similar to
placebo for mesalazine.161 A subsequent clinical trial has
confirmed no difference in adverse events between Eudragit-L
and ethycellulose mesalazine compounds.162 Acute intoler-
ance occurs in 3% and may resemble a flare of colitis. Renal
impairment (including interstitial nephritis and nephrotic
syndrome) is rare and idiosyncratic. A population-based
study found the risk (OR 1.60, CI 1.14–2.26 compared to
normal) to be associated with the disease as a rare extra-
intestinal manifestation, rather than the dose or type of
mesalazine.1635.4.1.3. Monitoring. Patients with pre-existing renal im-
pairment, significant co-morbidity or those taking additional
potentially nephrotoxic drugs should have renal function
monitored during 5-ASA therapy. Many clinicians believe
that creatinine and full blood count should be monitored
every 3–6 months during aminosalicylate therapy, although
there is no evidence favouring one monitoring regime over
another.
5.4.2. Corticosteroids for active UC
5.4.2.1. Efficacy of steroids. There have been only two
placebo controlled trials of conventional oral steroids for
outpatients with active UC,39,164 giving an NNT of 2 (95% CI
1.4–5.0).28 A meta-analysis confirms clinical benefit of
standard glucocorticosteroids over placebo for UC remission
(RR of no remission=0.65; 95% CI 0.45–0.93).20 The benefit
of intravenous steroids for patients admitted with severe
colitis is discussed in Section 1.2.4. Adverse effects and
monitoring of steroid therapy are the same as described in
the Consensus guidelines on Crohn's disease.165,166
5.4.3. Anti-TNF therapy for active UC
5.4.3.1. Efficacy of infliximab. A systematic review of the
efficacy of infliximab for treating patients with moderate to
severe UC refractory to corticosteroids and/or immunomod-
ulators concluded that it was effective for inducing clinical
remission, clinical response, promoting mucosal healing, and
reducing the need for colectomy in the short term.148 It
comprised seven RCTs and reported that infliximab (three
infusions at 0, 2, and 6 weeks) was more effective than
placebo in inducing clinical remission at week 8 (RR 3.22,
95% CI 2.18–4.76). A single infusion of infliximab was also
more effective than placebo in reducing the need for
colectomy within 90 days after infusion (RR 0.44, 95% CI
0.22–0.87).76 The ACT 1 and 2 studies are the pivotal placebo
controlled trials demonstrating benefit for infliximab over
placebo in outpatients with active UC refractory to one or
more conventional therapies.109 ACT 1 was a 364 patient study
comparing infliximab 5 mg/kg, 10 mg/kg, or placebo at 0, 2
and 6 weeks, then every 8 weeks for a year. The primary
endpoint was clinical response at week 8 (≥30% and a 3
point decrease in the Mayo activity index, with virtual
cessation of rectal bleeding). This was achieved in
37.2% (placebo), 69.4% (5 mg/kg) and 61.5% (10 mg/kg,
pb0.001). Pre-defined secondary endpoints included re-
mission (14.9%, 38.8% and 32.0% respectively) and mucosal
healing (33.9%, 62.0%, and 59.0%). ACT 2 was an almost
identical trial of 364 patients, which also included patients
refractory to 5-ASA alone (26% of the trial population).
Response (and remission) rates at week 8 were 29.3% (5.7%)
for placebo, 64.5% (33.9%) for 5 mg/kg, and 69.2% (27.5%)
for 10 mg/kg (pb0.001 for infliximab groups compared to
placebo). Further analysis of the ACT 1 and 2 trial data
reports a cumulative incidence of colectomy through
54 weeks of 10% for infliximab and 17% for placebo (p=0.02;
absolute risk reduction 7%).139
5.4.3.2. Efficacy of adalimumab. Two recently presented
placebo-controlled trials have assessed the efficacy of
adalimumab in patients with moderately active UC despite
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exposure to anti-TNF therapy).144,167 A randomised double-
blind placebo-controlled trial compared adalimumab
160 mg/80 mg/40 mg eow, adalimumab 80 mg/40 mg eow
and placebo in 390 anti TNF naïve outpatients with active
UC.144 The primary endpoint of clinical remission at week
8 was achieved in 18.5% of patients in the adalimumab 160/
80 group (p=0.031 vs placebo), 10.0% in the adalimumab
80/40 group (p=0.833 vs placebo) compared with 9.2% in
the placebo group. The second trial included 494 patients
with active treatment refractory UC (40.3% with prior
exposure to anti-TNF) randomised to adalimumab 160 mg/
80 mg/40 mg eow or placebo.167 The co-primary endpoints
were proportion of patients with (1) clinical remission at
week 8; (2) clinical remission at week 52. Clinical
remission was achieved in significantly more patients
receiving adalimumab than placebo at week 8 (16.5% and
9.3%; p=0.02) and week 52 (17.3% and 8.5%; p=0.01).
Clinical remission rates with adalimumab were higher in
patients who were naïve to anti-TNF therapy at baseline
than those who had prior exposure at both week 8 and week
52 (21.3% vs 9.2% and 22% vs 10.2% respectively). Finally
several small case series have reported benefit of
adalimumab in patients with active UC previously exposed
to infliximab with up to 27% entering clinical remission in
the short term.168–171
Most recently, the anti-TNF antibody golimumab has been
shown to induce clinical remission and mucosal healing.
Treatment with golimumab in a randomised controlled trial
at weeks 0 and 2 (400/200 mg, 200/100 mg, or placebo,
n=771) significantly induced clinical remission (17.8% and
18.7% vs 6.3% on placebo, respectively pb0.0001), as well as
mucosal healing at week 6 (400 mg/200 mg: 45%; p=0.0001;
200 mg/100 mg: 43%; p=0.0005 vs. placebo: 29%) suggesting
that several anti-TNF antibodies favour mucosal healing in
ulcerative colitis.172
5.4.3.3. Summary. Despite positive large well conducted
placebo-controlled clinical trials for both infliximab and
adalimumab in patients with active UC, a large therapeutic
gap persists. Induction and maintenance infliximab achieves
steroid free remission in 21% of patients at 7 months and
26% at 12 months (see Section 5.3.3).109 Adalimumab
160 mg/80 mg/40 mg eow delivers steroid-free remission
in 13.3% at week 52.173 It is important to consider these
results, because the Consensus stresses the importance of
achieving steroid-free remission. It is possible that the
rigid endpoints and assessments used in clinical trials
mask the true clinical impact of the therapy. A real
life observational cohort study has reported short
term clinical response rates for both adalimumab and
infliximab in excess of 80% with no difference between
the two drugs.150 Patient selection and the use of
concomitant therapies may also be important. The
recently presented UC-SUCCESS trial (Section 5.3.4) sug-
gests that early use of infliximab and azathioprine
combination therapy in patients with active colitis naïve to
immunomodulator therapy may yield steroid-free remission
rates of up to 40% at week 16.143 The benefit of concomitant
thiopurine therapy with infliximab was confirmed by
enhanced clinical outcomes in the small number of patients
(23/121) with UC included in a large cohort study.174Predictors of a poor response to infliximab that have been
reported include older age at first infusion, ANCA+ve/ASCA−ve
serotype,104 an undetectable trough infliximab level175 and
specific gene array profiles.176 Further studies are needed to
define the appropriate patient population, the benefits of
concomitant medication and any difference in efficacy for the
available anti-TNF therapies.5.4.3.4. Adverse effects of anti-TNF therapy. Treatment
with anti-TNF therapy is relatively safe if used for
appropriate indications. Adverse events in the ACT stud-
ies109 were not different to those expected from large
experience of treating Crohn's disease.177,178 Likewise no
new safety signals were detected in the adalimumab
trials.144,149,173 Nevertheless, in common with other
biological therapies there is a risk of serious infection,
demyelinating disease and associated mortality. In the
combined analysis of 484 patients with UC who received
infliximab in the ACT trials there were 8 who developed
pneumonia, 1 tuberculosis and 1 histoplasmosis (who later
died) as well as 4 neoplasia (all probably pre-existing, but
presenting in the trial period) and 3 neuropathies (2 optic
neuritis, 1 multifocal motor), equivalent to 3.5% (17/484). By
contrast, in the 244 who received placebo there was just 1
basal cell carcinoma. Prolonged medical therapy for a
potentially pre-malignant condition with anti-tumour necrosis
factor therapy creates its own anxieties. Tighter surveillance
to detect dysplasia may be necessary, although no evidence-
based recommendations can currently be given.
5.4.4. Other biological therapies
Despite the proliferation of biological therapies, only few
have shown benefit in appropriately designed clinical trials in
UC.
Vedolizumab (MLN-02–α4β7 integrin antagonist) was
given to 181 patients with moderately active UC.179 Clinical
remission rates at week 6 were 33% and 32% for 0.5 mg
and 2.0 mg/kg respectively, compared to 14% on placebo
(p=0.03). The phase 3 study for ulcerative colitis (300 mg iv
at days 1 and 15; n=225 vs placebo n=149) has reported
clinical remission in 16.9% vs 5.4% on placebo and mucosal
healing (Mayo endoscopy scoreb2) at week 6 (41% compared
to 25% on placebo) suggesting that blockade of T cell homing
in the gut may favour mucosal healing in ulcerative colitis.180
It was well tolerated and its novel mechanism of action as
well as its potential to maintain remission make it very
appealing. The apparently low remission rates with this
and other recently reported studies (e.g. golimumab, above)
are a feature of increasingly robust endpoints for defining
remission.159
Visilizumab, an anti-CD3 monoclonal antibody binding to
activated T-cells, induces apoptosis. A Phase III study in
intravenous steroid-resistant UC showed no benefit in
patients with iv steroid refractory severe UC.181
Although one IL-2 receptor (CD25) inhibitor, basiliximab,
has shown potential in open studies for steroid-refractory
UC182 another CD25 inhibitor, daclizumab, was ineffective in
a controlled trial of 159 patients with moderately active
UC.183
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tor) has not shown benefit in a phase III trial in ulcerative
colitis.184
Interferon-alpha induces anti-inflammatory cytokines
(IL-1RA, amongst others) and down regulates IL-13, giving
it a potential role in the treatment of active UC. A trial of 60
patients randomised to weekly injections of pegylated inter-
feron alpha at 1.0 μg/kg, 0.5 μg/kg, or placebo for 12 weeks
showed no consistent differences between the groups.185 An
American–European review on biological therapy for UC has
been published.186
Tofacitinib, an oral inhibitor of Janus kinases 1, 2, and 3,
which is expected to block signalling involving gamma
chain-containing cytokines including interleukins 2, 4, 7, 9,
15, and 21, has been evaluated in a double-blind, placebo-
controlled, phase 2 trial in 194 adults with moderately to
severely active ulcerative colitis.187 Patients were randomly
assigned to receive tofacitinib at a dose of 0.5 mg, 3 mg,
10 mg, or 15 mg or placebo twice daily for 8 weeks. Clinical
response at 8 weeks occurred in 32%, 48%, 61%, and 78% of
patients receiving tofacitinib at a dose of 0.5 mg (p=0.39),
3 mg (p=0.55), 10 mg (p=0.10), and 15 mg (pb0.001),
respectively, as compared with 42% of patients receiving
placebo. Clinical remission (defined as a Mayo scoreb/=2,
with no subscoreN1) at 8 weeks occurred in 13%, 33%, 48%,
and 41% of patients receiving tofacitinib at a dose of 0.5 mg
(p=0.76), 3 mg (p=0.01), 10 mg (pb0.001), and 15 mg
(pb0.001), respectively, as compared with 10% of patients
receiving placebo. There was a dose-dependent increase in
both low-density and high-density lipoprotein cholesterol.
Three patients treated with tofacitinib had an absolute
neutrophil count of less than 1500. Long-term data on
efficacy and on long‐term safety are needed, as potential
immunosuppression and increase in lipids may affect long-term
use.5.4.5. Thiopurines
5.4.5.1. Efficacy of azathioprine/mercaptopurine. A
meta-analysis which reviewed 30 non controlled studies
and analysed 7 controlled studies has confirmed that
thiopurine drugs are more effective than placebo for the
prevention of relapse in UC, with an NNT of 5 and an
absolute risk reduction of 23%.188 However, data on
thiopurines for active UC are few.189 Data from the well
conducted study on steroid-dependent active UC141 are
discussed in Section 1.3.3. Immunomodulators should be
started in steroid-dependent and steroid-refractory pa-
tients. Their successful introduction is associated with
colectomy-free survival in patients with severe UC treated
with ciclosporin to induce remission.90 The use of concom-
itant thiopurine therapy in patients receiving induction and
maintenance infliximab has been discussed in Section
5.4.3.143,174 The role of thiopurines for maintenance of
remission is discussed in Section 6.2.2.
5.4.6. Methotrexate
5.4.6.1. Efficacy of methotrexate. Prospective studies on
methotrexate for UC are small, use varying doses or routes
of administration and have inconsistent outcomes.190–192The only randomised placebo-controlled trial using a dose of
12.5 mg per week of oral methotrexate in UC showed no
benefit190 and a Cochrane database systematic review
concludes that there is insufficient evidence to support
its use at present.193 A randomised comparison of oral
methotrexate 15 mg/week with mercaptopurine 1.5 mg/
kg/day and 3 g/day 5-ASA for 72 steroid-dependent patients
(34 UC and 39 Crohn's) showed a remission rate at 30 weeks of
79% for mercaptopurine, 58% for methotrexate 25% for 5-ASA
(pb0.05 vs MP, ns vs methotrexate).191 A retrospective review
also suggests benefit in both thiopurine-intolerant and
thiopurine-refractory patients.194 However until data from
well designed randomised placebo-controlled trials such as
the GETAID-ECCO Meteor trial are available, it cannot
be considered an alternative to thiopurines for steroid-
dependent UC (see also Section 6.2.5).
5.4.7. Calcineurin inhibitors (ciclosporin and tacrolimus)
5.4.7.1. Efficacy of ciclosporin. Details of the role of
ciclosporin and tacrolimus for UC are given in Sections 5.2.4,
5.2.5, 5.3.4 and 5.3.5.
5.4.7.2. Dose and monitoring. Low dose ciclosporin (2 mg/
kg iv) induction therapy has largely addressed concerns
about early toxicity. In the largest randomised study of
ciclosporin to date, 73 patients were randomised to either
2 mg/kg or 4 mg/kg of intravenous ciclosporin.55 Response
rates at 8 days were similar in both groups (86% and 84%
respectively), with 9% coming to colectomy in the 2 mg/kg
group and 13% in the 4 mg/kg group. The study was too small
to show a difference in serious side effects, but there was
less hypertension in the lower dose group. The majority of
ciclosporin side-effects are dose-dependent. At the 2 mg/kg
dose, the mean ciclosporin concentration on day 4 was
24664 ng/mL, compared to345146 ng/mL with the 4 mg/kg
dose. Suitable target levels to induce remission are not
known, but in responders on oral medication, whole-blood
trough levels of 150–250 ng/mL using a monoclonal radio-
immunoassay are generally considered satisfactory. It is
said that 2 h post-dose peak levels give the best estimate of
drug exposure by correlating with the pharmacokinetic area
under the curve195 and an appropriate target appears to be
700 ng/mL, but this has not been correlated with efficacy
for UC.
Tacrolimus is more effective when given at a dose that
achieves a trough concentration of 10–15 ng/mL.93 The
initial oral dose in this randomised trial of 60 steroid-
refractory patients with active UC was 0.05 mg/kg/day,
increased according to the trough level after 24 h. 13 (68%)
achieving this trough level responded within 2 weeks,
compared to 8 (38%) achieving a lower trough level
and 2 (10%) in the placebo group. None had a complete
response. Possession of specific ACB1 single nucleotide
polymorphisms may predict response to appropriately dosed
tacrolimus.196
5.4.7.3. Adverse effects of calcineurin inhibitors. Hyper-
tension, paraesthesiae, or tremor and headache are the
commonest adverse events. Hypomagnesaemia, renal im-
pairment, or gastrointestinal upset affect around half of the
patients.93 Intravenous ciclosporin should be avoided in
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patient group experience increased neurological side effects.
Tacrolimus may induce diabetes. Opportunistic infection is
the main concern; 3/86 patients (3.5%) died of opportunistic
infections (1 of Pneumocystis jiroveci (carinii) pneumonia and
2 of Aspergillus fumigatus pneumonia) in a series of patients
treated with ciclosporin from a major specialist centre.197
Opportunistic infections and the value of chemoprophylaxis is
the topic of a separate ECCO Consensus.60
5.4.8. Alternative therapies whose role remains to be
established
5.4.8.1. Antibiotics. The main role of antibiotics in
patients with active UC is the treatment of co-existing
enteric infection with Cl. difficile.61–63 Antibiotics as an
adjunct to steroids do not alter the outcome of severe
colitis (Section 5.2.4,72–74,198–200). A randomised placebo-
controlled trial in 210 patients reported that a combination
of amoxicillin 1500 mg/day, tetracycline 1500 mg/day,
and metronidazole 750 mg/day for 2 weeks resulted in
clinical response at 3 months of 44.8% compared to 22.8% in
the placebo group (p=0.0011).201 A meta-analysis of the
benefit of antibiotics in patients with active UC that only
included parallel-group randomised controlled trials stud-
ied 9 RCTs with 662 patients.202 There was a statistically
significant benefit for antibiotics inducing remission (RR of UC
not in remission=0.64; 95% CI=0.43–0.96). However, there
was moderate heterogeneity (I2=69%) and the antibiotics
assessed were different single or combination strategies. The
authors concluded that antibiotic therapy may induce remis-
sion in active UC, but the diverse number of antibiotics tested
means the data are difficult to interpret.
5.4.8.2. Helminths. Observations that there is an epide-
miological mismatch between UC and helminth infections,
together with experimental evidence that several hel-
minths moderate immune-mediated models of colitis lead
to therapeutic trials of Trichuris suis ova. In a randomised
trial of 54 patients with mild-moderately active UC, 3/30 of
those treated with 2500 T. suis ova every 2 weeks for
12 weeks achieved remission compared to 1/24 given
placebo (ns), with a response in 43% and 17% respectively
(p=0.04).203 The optimal dose, interval and duration of
treatment need to be established and the response confirmed
in a larger study.
5.4.8.3. Heparin. Heparin promotes epithelial restitution
and repair in addition to anticoagulant properties. Out of
two small controlled trials of unfractionated heparin and
three using low molecular weight heparin in up to 100
patients, only the smallest trial has shown benefit for
active UC (review in204). A novel colonic delivery system for
low molecular weight heparin using MMx technology
appeared safe and effective in a small open label trial,205
although results from larger controlled trials are required
to confirm its therapeutic impact.
5.4.8.4. Leucocytapheresis. Leucocytapheresis involves
extracorporeal removal of leucocytes through an adsorptive
system of cellulose acetate beads (Adacolumn®, Otsuka
Pharmaceuticals), or a polyester fibre filter (Cellsorba®,Asahi Medical Company). The former removes 65% of neutro-
phils, 55% monocytes, and 2% lymphocytes whilst the latter
removes up to 100% of neutrophils andmonocytes, and 20–60%
lymphocytes. Sessions last an hour, during which time 2–3 L of
blood is drawn from one arm, filtered, and infused into the
other arm. A course of treatment is typically 5–10 sessions at
intervals of 1–2/week. Several observational and randomised
studies206–213 and two unusually designed randomised trials
comparing leucocytapheresis with prednisolone212 or a sham
column211 have suggested benefit. A largewell designed clinical
trial comparing active to sham apheresis has shown no
significant benefit for the treatment in 168 patients with active
UC.210 A subsequent systematic review concludes that although
there may be some benefit in selected patients groups,
methodological issues with the majority of published trials
prevented a rigorous meta-analysis.214 It has wide-spread
acceptance in Japan. Expense may limit its use, but the
outcome of controlled trials will govern its future role in
Europe.
5.4.8.5. Probiotic therapy. There is insufficient evidence
for the use of T. suis ova, Saccharomyces boulardii, or
Bifidobacteria in the treatment of UC [EL5, RG D]. The
majority of trials of probiotics for ulcerative colitis have
assessed their benefit in the maintenance of remission.215 A
Cochrane database systematic review of trials that investi-
gated the therapeutic benefit of probiotics for the induction
of remission in patients with active ulcerative colitis did not
find any study that reported a benefit over placebo.216 Since
that time a placebo-controlled trial of VSL#3 in 144 patients
with relapsing, mild to moderate UC despite mesalazine and
or immunosuppressants reported significantly more pa-
tients experiencing a clinical response with VSL#3 than
placebo.217
5.4.8.6. Other complementary therapies. Other comple-
mentary medicines have been studied in small studies or
in countries where randomised, double-blind, placebo con-
trolled trials are not the practice norm for judging themerits of
therapy. Because of sample size, study design, concomitant
therapies and questionable transferability, the following agents
can not currently be recommended for treating UC, either
for active disease or as maintenance: acupuncture,218–220
Boswellia serrata gum,221,222 prebiotic germinated barley
foodstuff,223–226 aloe vera gel227 and other herbalmedicines.228
A report on curcumin maintenance therapy (2 g daily,
added to aminosalicylates for 6 months) showed a signal
for benefit in a double-blind, placebo controlled trial of
89 patients.229 This needs confirmation and illustrates the
need to explore the benefit of complementary medicines
using the same rigorous clinical trials as conventional
therapy.230 In a recent study an extract of the herb
Andrographis paniculata (HMPL-004)—used in Chinese
medicine and shown to prevent colitis in animal models
—was compared to 4500 mg/day of slow release
mesalazine in patients with mild-to-moderately active
ulcerative colitis.231 In this clinical trial 120 patients at
five centres in China were randomised. There was no
significant difference between the two treatment groups
indicating a treatment effect of the herbal product.
However, this was a pilot study. It was not powered to
demonstrate non-inferiority. HMP-004 is an ethanolic
1006 A. Dignass et al.extract, the main known components are diterpene
lactones; however, the exact composition may vary
between batches. The effective component is not known;
therefore it is difficult to standardise the preparation. The
study has only been performed in China and therefore no
data in Caucasian patients are available. As outlined above
confirmation for those data is required before further
conclusions can be drawn.
5.5. Preparation for the period after treatment of
active disease
A patient's response to remission induction therapy should be
followed for several weeks. If treatment is effective, the
patient should continue until symptomatic remission is
achieved or further improvement ceases. An outcome other
than steroid-free remission after treatment of active disease
is considered unacceptable, whether or not immunomodula-
tors or biological therapy is used. Maintenance therapy is
recommended after successful medical treatment of active
disease. If a patient experiences a disease flare whilst taking
maintenance therapy appropriate induction therapy for the
acute flare is required.
6. Maintenance of remission
6.1. General
6.1.1. Maintenance therapy trial design
Most trials of maintenance therapy for UC have enrolled
patients in clinical and endoscopic remission. In such
studies, steroids are typically not permitted as concomitant
therapy. The endpoint is the absence of relapse (or failure to
maintain clinical remission) after 6 or 12 months.2 Clinical
relapse is defined by an increase in stool frequency and
recurrence of rectal bleeding, confirmed by endoscopy
(Section 1.2.6). This is not the only approach to the evalua-
tion of maintenance therapy, as more recent trials have
assessed both induction and subsequent maintenance at the
same time (e.g. ACT trials of infliximab109). Using this
approach, the clinical response at week 8 was defined as the
primary endpoint, and the efficacy of maintenance therapy
evaluated as a secondary endpoint (Section 6.2.3). However,
the pivotal endpoint that matters to patients is clinical
remission with complete, corticosteroid discontinuation in
those who were receiving steroids at baseline. Nevertheless,
the definition of remission varies between trials, which
makes comparisons difficult.159
ECCO Statement 6A
The goal of maintenance therapy in UC is to maintain
steroid-free remission, clinically [EL1, RG A] and
endoscopically defined [EL2, RG B]
6.1.2. Pattern of disease
More than half of patients with UC have a relapse in the year
following a flare. In clinical trials designed for the maintenance
of remission in patients with clinical remission at baseline,clinical relapse rates amongst patients receiving placebo range
from 29% to 43% at 6 months, and from 38% to 76% at
12 months.2,9,232 A population-based study carried out in the
county of Copenhagen,233 described the outcome in 1575
patients in the first 5 years following diagnosis of UC between
1962 and 2005. In the most recent period, the percentage of
patients experiencing an ‘indolent’ course (no relapse during
the first 5 years after diagnosis) was 13%, whilst 74% had
‘moderate’ course (two or more relapses within the first
5 years, but less than every year), and 13% had an ‘aggressive’
course (disease activity at least every year during the first
5 years). This highlights potentially confusing use of the term
‘moderate’ to refer to the pattern of disease, rather than the
activity at a point in time (Sections 11.2, 3.2.1). Furthermore,
grouping activity into 5-year periods seems too long for
everyday practice, although relevant from an epidemiological
perspective. The preferred alternative is to define relapse as
infrequent (≤1/yr), frequent (≥2 relapses/yr), or continuous
(persistent symptoms of active UC without a period of
remission).44
6.1.3. Impact of the definition of remission on long term
outcome
It is possible that the absence of a standardised definition
of remission has contributed to a self-perpetuating cycle of
suboptimal therapy in UC.159 Long-term prognostic studies
show low rates of remission (b50% of patients), and therefore
new and better (or better use of old) therapies are needed. It
is only now becoming apparent that a stringent endpoint for
remission (clinical plus endoscopic remission) is related to
longer duration of remission. For example, an endoscopic
score of 0 (defined as complete mucosal healing) applied to a
post-hoc analysis of the ACT 1 and 2 trials revealed that
patients with healing at week 8 had a four-fold increased
likelihood of remission at week 30 of infliximab treatment.234
This may be expected, but needs to be confirmed if clinical
practice is to change. Patients assessed after induction
therapy by an index that did not incorporate endoscopy
were less likely to be in remission one year later than those
whose remission was defined by endoscopic, as well as
clinical criteria.235,236 Finessing the endoscopic mucosal
friability component of the Sutherland Index to develop the
more stringent ‘Modified UC-DAI’ has affected long term
remission rates in prospective clinical studies. Using
the Modified UC-DAI, patients receiving Multi-Matrix System
(MMX) mesalazine achieved and maintained remission
rates N60% at four months and one year follow-up.237,36
ECCO Statement 6B
Maintenance treatment is recommended for all pa-
tients [EL1a, RG A]. Intermittent therapy is acceptable
in a few patients with disease of limited extent [EL5,
RG D]6.1.4. Risk factors for relapse
Few prospective studies have assessed risk factors for
relapse in patients with inactive UC.238–242 In one study of 92
1007Second European Consensus on the diagnosis and management of ulcerative colitispatients, a shorter duration of current remission and a higher
relapse frequency were predictive of further relapse.238 In a
second study of 64 patients, the frequency of previous
relapses, extraintestinal manifestations and a low-fibre diet
were independent variables associated with a higher risk of
relapse.239 In another study of 74 patients including various
biomarkers and clinical measures, a younger age, multiple
previous relapses (for women), and basal plasmacytosis on
rectal biopsy specimens were independent predictors of
relapse.240 This study did not confirm the two-fold increase
in relapse rate in those with persisting active inflammation
(polymorphonuclear leukocytes in the rectal mucosa) ob-
served in two earlier histopathology studies.243,244
The impact of life events on relapse of UC has been
examined by a number of studies241,242,245 with contradictory
results. Nevertheless, in the best prospective study to date,
704 patients with quiescent IBD (38% with UC) from the
University of Manitoba IBD disease registry were followed with
questionnaires every 3 months for 12 months.246 Only stress
(HR 2.46; 95% CI 1.56–3.89) whether perceived, negative
affect, or any major stressful event and being single (OR 1.79,
95% CI 1.03–3.13) were associated with a higher risk of relapse
on multivariate analysis and not use of NSAIDs, antibiotics, or
infection. Adherence to medical therapy still appears to be
the governing factor associated with relapse, since the risk of
relapse was more than 5-fold higher (OR 5.5, 95% CI 2.3–13.0)
amongst 99 patients who collected b80% of their prescriptions
for maintenance mesalazine.247
ECCO Statement 6C
Choice of maintenance treatment in UC is determined
by disease extent [EL1b, RG B], disease course
(frequency of flares) [EL5, RG D], failure of previous
maintenance treatment [EL5, RG D], severity of the
most recent flare [EL5, RG D], treatment used for
inducing remission during the most recent flare [EL5,
RG D], safety of maintenance treatment [EL1b, RG B],
and cancer prevention [EL2a, RG B]
Patients with disease requiring steroids probably have a
different outcome to the overall population of patients with
UC. In a population-based study from Olmsted County,
Minnesota, the outcome of 183 patients with UC diagnosed
between 1970 and 1993 was analysed one year after a first
course of steroids.248 Amongst the 63/183 patients treated
with corticosteroids, 49% had a prolonged response, 22% were
steroid dependent and 29% came to colectomy, but only 3/183
were treated with AZA/MP (see also Section 5.4.2).
Both mucosal healing and a previous episode of acute
severe colitis impact on the key outcome of colectomy. In a
population-based study from South East Norway, 423/519
patients with UC completed the 10-year follow-up. 53 died
and 43 were lost to follow-up. The cumulative colectomy
rate after 10 years was 9.8% (95% CI 7.4–12.4%). Initial
presentation with extensive colitis or acute severe colitis
tripled the risk of subsequent colectomy (HR 3.57, 95% CI
1.60–7.96), whilst age ≥50 years at diagnosis reduced the
risk by 3-fold (HR 0.28, 95% CI 0.12–0.65). Relapsing disease
occurred in 83%, but half (48%) of the patients were relapsefree during the last 5 years. Mucosal healing 12 months after
diagnosis was associated with a lower colectomy rate (2% vs
8% without mucosal healing, p=0.02).249 Two studies have
now shown that admission to hospital is a key factor in
predicting colectomy250,251 In the Oxford cohort of 750
patients, 186 had at least one episode of acute severe
colitis. The overall colectomy rate was 12.4% (93/750), but
it was 39.8% (74/186) of patients with one or more episodes
of ASC (pb0.0001) and just 3.4% (19/564) in those with no
admission.2156.2. Medications for maintenance of remission
Details of the action, dosage, side effects and monitoring of
aminosalicylates, steroids, thiopurines, and infliximab are in
the Active Disease section.
Options for a stepwise escalation of maintenance therapy
include dose escalation of oral/rectal aminosalicylates [EL1,
RG A], the addition of azathioprine/mercaptopurine [EL2,
RG B] or Infliximab/anti TNF therapy [EL1, RG A]. Short term
use of systemic or topical steroids may be required when a
rapid response is needed [EL1, RG A].
6.2.1. Aminosalicylates
ECCO Statement 6D
Oral 5-aminosalicylate (5-ASA) containing compounds
are the first line maintenance treatment in patients
responding to 5-ASA or steroids (oral or rectal) [EL1a, RG
A]. Rectal 5-ASA is the first line in maintenance in
proctitis and an alternative in left-sided colitis [EL1b, RG
A]. A combination of oral and rectal 5-ASA can be used as
a second line maintenance treatment [EL1b, RG B]
6.2.1.1. Oral 5-ASA. The most recent version of the
Cochrane meta-analysis showed that the Peto odds ratio
for failure to maintain clinical or endoscopic remission
(withdrawals and relapses) for oral 5-ASA versus placebo was
0.47 (95% CI 0.36–0.62), with a number-needed-to-treat
(NNT) of 6.252 Numerous randomised controlled trials (RCTs)
designed to evaluate the efficacy of oral 5-aminosalicylates
(5-ASA)—including sulfasalazine, various mesalazine formu-
lations and olsalazine—for maintaining remission have been
conducted in the past.34,236,237,253–262
6.2.1.2. Rectal 5-ASA. Several RCTs have compared rectal
mesalazine in various formulations and regimens with
placebo for maintenance of remission in distal UC.263–268
At 12 months, failure to maintain clinical or endoscopic
remission was 20–48% in the active arms compared to 47–89%
in the placebo arms. In all but one of the trials, the differences
in failure to maintain remission between active and placebo
groups were statistically significant. The only RCT that failed
to demonstrate efficacy of 5-ASA suppositories264 followed
a three times a week regimen; the difference between the
two arms was significant at 3, 6 and 9 months but did not
reach the significance level at 12 months. Other trials have
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regimens, either alone or in combination with oral 5-ASA. A
meta-analysis which included the two placebo-controlled
trials, showed a superiority of rectal mesalazine over placebo
for remission maintenance at 1 year (OR 16.2, 95% CI
4.7–55.9).269
6.2.1.3. Combining oral and topical 5-ASA therapy. There
have been two RCTs comparing combination treatment with
oral mesalazine plus intermittent mesalazine enema to oral
mesalazine alone for maintaining remission. Remission rates
were higher in patients receiving the combination.266,270
It is therefore clear that oral or rectal 5-ASA is superior to
placebo in maintaining remission in UC. The data suggest that
rectal 5-ASA has equivalent or slightly superior efficacy to
oral mesalazine in distal UC. The combination of oral
mesalazine and intermittent rectal 5-ASA appears to provide
further benefit. Although most authors in the studies claimed
that patients found long-term rectal treatment acceptable, a
postal survey of the UK patients showed that 80% preferred
oral treatment alone.271 However, in another study in Spain,
5-ASA suppositories were generally well tolerated and consid-
ered comfortable for treatment of at least one year.272 The
choice and options should be discussed with patients. Adding
rectal therapy is a treatment option for patients who have
relapsed on oral 5-ASA alone, although adherence to prescribed
therapy should be addressed.
ECCO Statement 6E
The minimum effective dose of oral 5-ASA is 1.2 g per
day [EL1a, RG A]. For rectal treatment 3 g/week in
divided doses is sufficient to maintain remission. The
dose can be tailored individually according to efficacy
and in some cases higher doses±topical 5-ASA is useful
[EL5, RG D]. Once daily administration of 5-ASA has
been proven to be at least as effective as twice or
three-times daily administration, with no increased
side effects [EL1a, RG A]. Although sulfasalazine is
equally or slightly more effective [EL1a, RG A], other
oral 5-ASA preparations are preferred for toxicity
reasons. All the different available preparations of
oral 5-ASA are effective [EL1a, RG A]. There is no
robust evidence to support the choice of any specific
5-ASA preparation for maintenance [EL1a, RG A]6.2.1.4. Dose–response effect. A dose–response for
maintenance of remission with mesalazine at doses greater
than 0.8 g/day has not been established. In an Italian
study, no difference was found in relapse rates at 1 year on
mesalazine 1.2 g compared to 2.4 g/day.235 Patients taking
the higher dose were in remission for longer than those on
the lower dose (median time in remission of 175 days vs
129 days, pb0.001), but it may be debated whether this is
clinically significant. For those with extensive UC, howev-
er, the benefit of the higher dose was more marked
(143 days versus 47 days, pb0.005). When the results for
patients in remission at 12 months were analysed after
stratifying for frequently relapsing disease (N3 relapsesper year) versus less frequent relapses, 2.4 g/day also
performed significantly better than 1.2 g/day (75% versus
33%, respectively). This post hoc analysis must, however,
be treated with caution.273 Another trial has also reported
a trend for benefit in subjects receiving the higher dose of
Pentasa 3 g/day compared with 1.5 g/day (p=0.051).274 As
with other studies of high doses of 5-ASA, there was no
increase in the frequency of adverse events. It is possible
that higher doses of maintenance oral mesalazine are
required in some patients, perhaps in those that required
high doses of oral 5-ASA to induce remission or those with
frequently relapsing disease, but at present, there is no
robust evidence to support this.275 There are also no data
supporting a dose–response relationship with rectal 5-ASA
for maintaining remission in distal UC, and no more than
1 g/day is required.
Several studies236,237,261,262 have compared different
dosing regimens for various 5-ASA formulations. Without
exception, they have all concluded that once daily
administration is, at least, as effective as twice or three
times administration of 5-ASA. The comparable efficacy
between once daily and divided dosing regimes in the
maintenance treatment of UC, obtained with different
mesalazine formulations, suggests that this effect is
generic to 5-ASA rather than compound-specific. Interest-
ingly, once daily administration of mesalazine has not
been found associated to an increase rate of side effects in
any of these studies. Taken together, in conjunction with
the likely improvement in patient convenience and adher-
ence to treatment, this make once daily administration of
5ASA compounds the first choice in maintenance therapy in
patients with UC.
6.2.1.5. Comparison of oral 5-ASA formulations. In a
Cochrane meta-analysis252 the odds ratio for the failure to
maintain clinical or endoscopic remission (withdrawals and
relapses) was calculated for several trials in which sulfa-
salazine and different 5-ASA formulations were com-
pared.235–237,260,274,276–284,259,236,237,261 The odds ratio was
1.29 (95% CI 1.05–1.57), with a negative NNT, suggesting
greater therapeutic effectiveness for sulfasalazine. Sulfa-
salazine and 5-ASA had similar adverse event profiles (OR 1.16,
95% CI 0.62–2.16, and OR 1.31, 95% CI 0.86–1.99 respective-
ly). However, the trials that compared 5-ASA and sulfasalazine
are likely to have been biased in favour of sulfasalazine,
because most trials enrolled sulfasalazine-tolerant patients,
which would have minimized sulfasalazine-related adverse
events.
Other studies have addressed the issue of whether 5-ASA
formulation influence its efficacy as maintenance treatment.
In a study by Ito et al.17 no differences were observed between
a pH-dependent and a time-dependent 5-ASA formulation. In a
study by Prantera et al. MMXmesalazine, 2.4 g once daily, was
as effective as Asacol® in maintaining UC remission.2596.2.1.6. Adherence to 5-ASA treatment. Adherence to
5-ASA therapy appears to be pivotal for improving outcome
in patients with UC. The adherence rate in 94 outpatients on
5-ASA with clinically quiescent UC for at least 6 months was
40% and the median amount of medication dispensed per
patient was 71% (8–130%) of that prescribed.285 Logistic
1009Second European Consensus on the diagnosis and management of ulcerative colitisregression found that a history of four or more prescriptions or
male gender increased the risk of non-adherence. Being
married, having extensive disease or having an endoscopy
within the past 24 months reduced non-adherence. In a pilot
study, patients were randomised to receive either once-daily
or conventional (two or three times daily), mesalazine for
maintenance of remission in UC.286 After 6 months, patients in
the once-daily arm appeared more satisfied with their
regimen and consumed more medication than those in the
conventional arm (90% vs 76%; p=0.07). The authors
concluded that once-daily oral formulations of 5-ASA were
likely to be a better therapeutic option with comparable
efficacy and improved adherence. An investigator-blinded
study of 362 patients randomised to receive Pentasa 2 g
once daily or 1 g twice daily, showed a 12% better remission
rate at 1 year (73.8% vs 63.6% respectively) in the once daily
dose group.236 Patient questionnaires showed significantly
greater compliance (pb0.05) and acceptability (pb0.001)
in the once daily group. Given the comparable efficacy
between once daily and divided dosing regimes for the
treatment of active UC with other mesalazine formulations,
this effect is likely to be generic rather than compound-
specific.236,237,261,2626.2.2. Thiopurines
6.2.2.1. Efficacy of thiopurines for maintenance of remis-
sion. Several RCTs evaluating the efficacy of thiopurines
azathioprine (AZA) and mercaptopurine (MP) for maintenance
of remission in UC have been performed.141,191,287–291 In a
Cochrane meta-analysis,292 six of these studies on 286
patients were considered. The study quality was judged
generally poor and the evidence for using thiopurines in UC is
weaker than that for Crohn's disease. AZA was shown to be
superior to placebo on the basis of four trials (OR for failure to
maintain remission 0.41, 95% CI 0.24–0.70). The results were
similar when analyses were limited to patients who had
successful induction of remission (data available for two
studies). There was no clear evidence of a dose–response
effect for AZA, or for use of co-medication with mesalazine in
these studies. Adverse effects occurred in 11/127 patients
receiving AZA, including acute pancreatitis (3 cases) and bone
marrow suppression (5 cases). Since this meta-analysis, a
further RCT has been published by Ardizzone et al.141 72
patients with active steroid-dependent UC were randomised
(investigator-blind) to AZA 2 mg/kg/day or mesalazine
3.2 g/day for 6 months. Steroid-free, clinical and endoscopic
remission was achieved in 53% on AZA, compared to 21% given
5-ASA (intention to treat analysis: OR 4.78, 95% CI 1.57–14.5).
This is the best trial to date.
Evidence to support the use of thiopurines for UC also comes
from observational cohorts in retrospective series.293–298 The
best amongst these is the 30 year cohort from the Oxford IBD
clinic between 1968 and 1999.294 In this series, the overall
remission rate in 346 patients with UC who were treated with
AZA was 58%, but increased to 87% amongst patients on
therapy for more than 6 months. The proportion of patients in
remission at 5 years was 62% applying a strict definition of
relapse, or 81% allowing for a brief relapse with a short
corticosteroid course. The median time to relapse after
stopping AZA was 18 months.6.2.2.2. Thiopurines after ciclosporin (or tacrolimus) for
induction of remission. Calcineurin inhibitors are rescue
therapy options for steroid-refractory UC (Section 5.2.5).
Since calcineurin inhibitors are best discontinued within
6 months because of side effects, these agents are generally
proposed as induction therapy until slower-acting immuno-
modulators such as AZA or MP become effective. AZA or MP is
introduced whilst the patient is still on ciclosporin (CsA) or
tacrolimus and steroids are being tapered. The justification
of thiopurines in this setting, even in patients who are 5-ASA
naive, is the high colectomy rate (36–69% in the 12 months
following introduction of CsA, Section 5.2.586,87,299,300).
Retrospective series have suggested that thiopurines reduce
the risk of colectomy after the induction period with
CsA.86,87,301,264 In another series 5/19 patients receiving AZA
(26%) underwent colectomy during the follow-up, compared
to 9/11 subjects (81%) who did not receive AZA maintenance
(p=0.01).299 Similar results have been reported from Chicago:
of 36/42 initial responders to CsA, 25 (69%) also receivedMP or
AZA, of whom 20% required colectomy vs 45% who did not
receive thiopurines during the 5 year follow‐up.86
After intravenous CsA, a switch to oral therapy occurs as
soon as a clinical response has been achieved, with a view to
acting as a ‘bridge’ until the therapeutic effect of AZA is
achieved. Nevertheless, the usefulness of the oral CsA bridge
has been challenged. In a retrospective series from Barce-
lona, all responders to iv CsA were treated with AZA, without
oral ciclosporin.302 Cumulative probabilities of relapse were
42%, 72% and 77% at 1, 3 and 5 years, and cumulative
probabilities of colectomy were respectively 29%, 35% and
42%. These are similar to or better than those reported in
the literature, so the authors concluded that the ‘bridging
step’ with oral CsA may not be necessary.
6.2.3. Anti-TNF therapy
ECCO Statement 6F
Azathioprine/mercaptopurine is recommended for
patients with mild to moderate disease activity who
have experienced early or frequent relapse whilst taking
5-ASA at optimal dose or who are intolerant to 5-ASA
[EL5, RG D], patients that are steroid-dependent [EL1a,
RG A] and for patients responding to ciclosporin (or
tacrolimus) for induction of remission [EL3, RG C]. In
patients responding to anti-TNF agents, bothmaintaining
remission with azathioprine/mercaptopurine [EL4, RGC]
and continuing anti-TNF therapy with or without
thiopurines [EL1a, RGA] are appropriate. In patients with
severe colitis responding to intravenous steroids,
intravenous ciclosporin or infliximab, azathioprine/
mercaptopurine should be considered to maintain remis-
sion [EL2b, RG3]. However, in patients responding to
infliximab continuing infliximab is also appropriate [EL4,
RGC]. The prior failure of thiopurines favours mainte-
nance with anti-TNF therapy [EL5, RGD]6.2.3.1. Efficacy for maintenance. Details of the ACT 1 and
2 studies are given in Section 5.4.3.109 In both studies, a
1010 A. Dignass et al.significantly higher proportion of patients had a clinical
response or remission on IFX at weeks 8 and 30 (and at
week 54 in the ACT 1 trial), compared to placebo. In ACT 1,
remission rates at week 54 were 35% (5 mg/kg), 34%
(10 mg/kg) and 17% (placebo). In ACT 2, remission rates at
week 30 were 26% (5 mg/kg), 36% (10 mg/kg) and 11%
(placebo). The proportion of patients with a sustained
clinical remission at all time points was 7% (placebo) and
20% (5 mg/kg) after 54 weeks in ACT 1, and 2% (placebo)
and 15% (5 mg/kg) after 30 weeks in ACT 2. The steroid-free
remission rates in the 74 patients receiving corticosteroids
at baseline were very modest, although still statistically
significant. In ACT 1, steroid-free remission at week 54 was
achieved in 24% (5 mg/kg), 19% (10 mg/kg) and 10%
(placebo). In ACT 2, the corresponding values at week 30
(7 months) were 18%, 27% and 3%. The rates of clinical
response and remission were similar between the subpopula-
tions of patients who were “corticosteroid-refractory”
(i.e., those receiving corticosteroids at baseline) and those
who were “not corticosteroid-refractory”.
In long-term follow up, 121 outpatients with refractory UC
treated with IFX were analysed for colectomy-free survival.
Secondarymeasureswere sustained clinical response and serious
adverse events. From the 81 patients (67%)with an initial clinical
response to IFX, 68% had a sustained clinical response. No
independent predictors of sustained clinical response could be
identified. Over amedian (IQR) follow-up period of 33.0 (17.0–
49.8) months, 21 patients (17%) came to colectomy. Indepen-
dent predictors of colectomy were absence of short-term
clinical response (Hazard Ratio 10.8, 95% CI 3.5–32.8,
pb0.001), a baseline CRP level ≥5 mg/L (HR 14.5, 95% CI
2.0–108.6, p=0.006) and previous intravenous treatment with
corticosteroids and/or ciclosporin (HR 2.4, 95% CI 1.1–5.9, p=
0.033).303 Complete mucosal healing has independently been
shown to be associated with a lower colectomy rate (95%
colectomy-free at week 54, compared to 80% with an
endoscopic Mayo Clinic subscore of 3, p=0.0004).234
Two randomised controlled trials have also demonstrated
the efficacy of the anti-TNF adalimumab (ADA) for main-
taining remission in patients with moderate to severe
UC.149,167 In a trial by Reinisch et al.,149 patients could
enter a 52-week open-label extension to receive ADA 40 mg
every other week (eow) as maintenance therapy after an
8-week, randomised, placebo-controlled induction period
with adalimumab or placebo. Of 390 patients in the primary
analysis population, 360 received open-label ADA eow and
117 had their dosages increased to weekly ADA. Remission
rates at Week 52 were 25.6% (non-responder imputation,
NRI) and 29.5% (mNRI). No deaths or cases of tuberculosis
were reported.149 In another study167 on the efficacy and
safety of ADA for induction and maintenance of clinical
remission in patients with moderate-to-severe ulcerative
colitis, adult patients with UC were randomised to placebo
or ADA (160 mg/80 mg, then 40 mg eow). Patients were
allowed previous anti-TNF therapy. In this trial, significantly
more ADA-treated patients achieved clinical remission,
clinical response, and mucosal healing at Week 8, Week 52,
and both Weeks 8 and 52, compared to placebo. Amongst
patients with corticosteroid use at baseline, significantly
more ADA-treated patients discontinued corticosteroids
before Week 52 and achieved clinical remission at Week
52, compared with placebo (13.3% vs. 5.7%).6.2.3.2. Combining IFX and immunomodulators. As with
Crohn's disease,304 the combination of IFX and a thiopurine
analogue or corticosteroids is probably justified to decrease
immunogenicity, which is the source of infusion reactions
and loss of response.305 The efficacy of IFX, AZA, or IFX plus
AZA was investigated in a 16-week, randomised, double-
blind, controlled trial (UC-SUCCESS trial) in biologic-naïve
patients with moderate–severe UC. A significantly greater
proportion of patients achieved steroid-free remission at
week 16 in the IFX+AZA arm compared to the AZA arm or IFX
monotherapy arm. Clinical response and mucosal healing
were higher in both IFX groups compared to the AZA
alone.143 Since antibodies to IFX occur early in the treat-
ment, the question of discontinuing the immunomodulator
has been addressed for Crohn's disease by the Leuven group.
Results from a single centre open-label randomised, with-
drawal trial suggest that the immunomodulator can be
stopped after 6 months with no loss of response to IFX over
2 years.306
A 2 year follow up of patients who received salvage
therapy with IFX for intravenous steroid-refractory UC
showed that 13/16 patients who received AZA avoided
colectomy (with or without oral 5-ASA) compared to 5/8 who
received 5-ASA alone.132
6.2.4. Probiotics
ECCO Statement 6GE coli Nissle is an effective alternative to 5-ASA for
maintenance [EL1b, RG A]6.2.4.1. Escherichia coli strain Nissle 1917. Three RCTs
have compared the E. coli strain Nissle 1917 to mesalazine
for maintenance of remission in UC. In the first study, 120
outpatients in a multicentre, double-blind, study received
1.5 g/day 5-ASA or 100 mg/day E. coli strain Nissle (corre-
sponding to 25×109 viable E. coli bacteria) for 4 days, and
then 200 mg/day.307 No concomitant medications were
permitted. After 12 weeks, 11% of patients receiving 5-ASA
and 16% of those receiving the probiotic patients relapsed.
The statistical power was limited by the short duration of
the study as relatively few patients relapsed. In addition, an
11–16% relapse rate within 3 months seems rather high.
Subsequently 116 patients with active UC were randomised
to receive either 5-ASA 2.4 g/day, reducing to 1.2 g/day
after remission, or 200 mg/day of E. coli strain Nissle.308 All
patients also received an initial 7 day course of oral
gentamicin and either rectal or oral steroids in variable
doses. The remission rate was 75% in the corticosteroid plus
5-ASA group, and 68% in the corticosteroid plus E. coli group
(ns). During the one year follow‐up, relapse occurred in 73%
of the 5-ASA group and 67% of the E. coli group (ns) after
weaning off steroids. This is a very high relapse rate for
reasons that are unclear, but the probiotic was no less
effective than 5-ASA. Finally, an equivalence study was
conducted.309 327 patients with UC in remission for
no longer than 12 months were treated with either 5-ASA
1.5 g/day or E. coli Nissle 1917 for 1 year. The relapse rate
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It was concluded that E. coli strain Nissle 1917 is not
inferior to the established standard 5-ASA for maintenance
of remission in UC, although the relapse rate in this last
study was still higher than expected.
In addition to these RCT, a more recent open-label pilot
study investigated the clinical benefit of E. coli Nissle (EcN)
1917 for maintenance therapy in young patients with UC. 34
patients with UC in remission aged between 11 and 18 years
were allocated either to EcN (2 capsules daily n=24) or
5-ASA (median 1.5 g/day, n=10), observed over one year.
This trial is clearly underpowered to show any difference or
equivalence, but the relapse rate was 6/24 in the EcN group
and 3/10 in the 5-ASA group. Data on the patients' global
health and development were favourable and no serious
adverse events were reported.3106.2.4.2. Other probiotics. No evidence has yet been
reported that any other probiotic is effective for maintaining
remission in patients with UC.311,312 With regard to the
probiotic mixture VSL#3, a 1-year placebo-controlled,
double-blind study assessed its efficacy for induction and
maintenance remission in children with active UC.313 A total
of 29 consecutive patients with newly diagnosed UC were
randomised to receive either VSL#3 or placebo in con-
junction with concomitant steroid induction and mesalazine
maintenance. All 29 patients responded to the induction
therapy. Remission (according to their definition) was
achieved in 13/14 patients (93%) treated with VSL#3 and
IBD therapy and in 4/11 patients treated with placebo and
IBD therapy (per protocol analysis pb0.001). During follow
up, 3/14 (21%) patients treated with VSL#3 and IBD therapy,
and 11/15 (73%) patients treated with placebo and IBD
therapy relapsed within 1 year of follow-up. No conclusions
about efficacy can be drawn.
6.2.5. Other treatments
6.2.5.1. Antibiotics. The potential benefit of adding cipro-
floxacin to conventional therapy has been investigated.314 In a
randomised, placebo-controlled, double-blind clinical trial,
ciprofloxacin (1–1.5 g/day) or placebo was administered for
6 months to 83 patients referred with active UC refractory to
conventional treatment. All the patients were initially treated
with a high, but decreasing dose of prednisone andwith 5-ASA.
The treatment failure rate was 21% in the ciprofloxacin-
treated group and 44% in the placebo group (p=0.02). The
study design was more appropriate for an induction rather
than a maintenance study and inclusion criteria, definition of
clinical response and concomitant therapies have been
criticised.315 Consequently ciprofloxacin should not be con-
sidered effective for maintaining remission in UC. In another
double-blind, randomised trial, metronidazole (0.6 g/day)
and sulfasalazine (2 g/day) were compared for maintenance
of remission in 40 patients with UC in remission for less than
12 months.316 After 1 year, metronidazole was found to be
slightly more effective than sulfasalazine. No significant side
effects were noted, and in particular, no paraesthesiae were
reported. These data were regarded as insufficient by the
Consensus to recommend antibiotics for maintenance of
remission in UC.6.2.5.2. Methotrexate. Data on methotrexate (MTX) for
maintenance of remission in UC are few. The single RCT was
principally designed for induction of remission in refractory,
active UC and used a dose of 12.5 mg orally/week that is
probably sub-therapeutic.190 Proportions of patients who
relapsed after first remission (MTX 64% vs placebo 44%) were
not significantly different. An open-label study compared
mercaptopurine (MP), MTX and 5-ASA in 72 steroid-
dependent IBD patients, included 34 with UC.191 Patients
on prednisone were randomly assigned in a 2:2:1 ratio
to receive MP 1 mg/kg, MTX 15 mg orally/week, or 5-ASA
3 g/day. All patients who achieved remission at week 30
were then included in a maintenance study for 76 weeks. A
significantly higher proportion of patients achieved remis-
sion in the MP group (79%) than in the 5-ASA group (25%),
with no statistical differences compared to the MTX group
(58%). For maintenance of remission, the higher rate was
found in the MP group (64%) compared to MTX (14%) and
5-ASA (0%).
Several retrospective series have been published.194317
Most of the included patients had failed or were intolerant of
azathioprine and were treated with MTX at various doses and
routes of administration. The response or remission rates
ranged from 30% to 80%, when the drug was given by
parenteral route in doses between 20 and 25 mg, suggesting
that some patients with UC may respond to MTX. MTX
(median oral dose 20 mg/week) was tolerated by 27/31
(87%) patients who had been unable to tolerate AZA. Of
those treated with MTX after failure with AZA, 5/11
patients had a colectomy, compared to 5/31 patients
intolerant of AZA.317 In another study, MTX induced a
response in 65% (15/23) of those who were either previously
intolerant and in 78% (7/9) of those who previously failed
with thiopurines.194 The results are heterogeneous and it is
possible that the dose of MTX is an important determinant
of efficacy, but the Consensus considered that there is
currently insufficient evidence to recommend MTX for
UC. A Cochrane systematic review reached the same
conclusion.193
6.3. Duration of maintenance therapyECCO Statement 6H
The general recommendation is to continue 5-ASA
maintenance treatment long-term [EL3b, RG C] since
this may reduce the risk of colon cancer [EL4, RG D]
6.3.1. Aminosalicylates
Two studies from Sweden and the UK were publishedto assess whether sulfasalazine was still effective at
preventing relapse in patients with UC with a long duration
of remission. In the Swedish study, the authors found no
statistical benefit to maintaining sulfasalazine for patients
who had been symptom-free on sulfasalazine for more than a
year.255 However, the number of patients was small, the
duration of follow-up only 6 months and patients were
selected on clinical symptoms without endoscopic or histolog-
ic criteria. In the UK study, sigmoidoscopy and rectal biopsy
were used at entry.254 The authors found that maintenance
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major effect at reducing relapse, even in the subgroup of
patients who had been on sulfasalazine for more than 3 years.
Twenty-six years later, an Italian double-blindwithdrawal RCT
included 112 patients with UC in clinical, endoscopic and
histological remission who had been on sulfasalazine or 5-ASA
for at least 1 year.318 Patients were randomised to oral
mesalazine 1.2 g/day or placebo for 1 year. Despite the small
numbers, patients were stratified according to the length of
disease remission prior to randomization. In patients with
disease remission for 1–2 years, mesalazine appeared signif-
icantly more effective than placebo for preventing relapse at
12 months (mesalazine 23% and placebo 49%, p=0.035). For
patients who had been in remission for more than 2 years
however, no statistically significant difference was observed
between relapse rates (5/28 vs 6/23, or 18% vs 26%,
respectively), but numbers were very small. The results of
this study should be regarded with caution, not only because
of the low power, but also because the trend was in favour of
continuing mesalazine.
ECCO Statement 6I
Due to limited evidence, no recommendation can be
given for the duration of treatment with azathioprine
or infliximab, although prolonged use of these medi-
cations may be considered if needed [EL4, RG D]
6.3.2. Thiopurines
There are few data on factors predicting response to
azathioprine (AZA) and uncertainty regarding the optimal
duration of treatment. In a retrospective analysis with 622
patients with either CD or UC, the remission rates at month
six were 64% and 87%, respectively. The proportions of
patients remaining in remission at one, three, and five years
were 0.95, 0.69, and 0.55, respectively. There was no
difference in relapse rates between CD and UC. After
stopping AZA, the proportions of patients remaining in
remission at one, three, and five years were 0.63, 0.44,
and 0.35 (222 patients) respectively. The duration of AZA
treatment did not affect the relapse rate after stopping
treatment (p=0.68).294
6.3.3. Anti-TNF therapy
Several studies, most of them neither prospective nor
randomised have reported long-term efficacy data of in UC
[reviewed in319]. A prospective study reported the long-term
outcome of IFX in less severe UC.320 The long-term effect of
IFX on disease activity, corticosteroid use and quality of life
in patients who had completed the ACT 1/2 trials and had
responded to IFX, who had then been enrolled in the
ACT-extension (n=229) study is reported. Of these 229
patients, 181 have been followed for 1 year and 92 for
2 years. The rates for little or no activity at weeks 56 and
104 from the ACT extension baseline were 92% and 97%
respectively. The 2-year rates of corticosteroid-free remis-
sion were 75% and 98%, respectively. Data on Adalimumab
beyond 1 year for UC have yet to be reported, but main-
tenance of effect in those who maintain response to anti-
TNF therapy after 1 year can be expected with continuedtreatment. No withdrawal study of anti-TNF therapy has
been reported in UC.
7. Surgery
7.1. General
Surgery for ulcerative colitis has been refined to offer patients
needing colectomy a better quality of life. Until the early
1980s, the gold standard for surgery was proctocolectomy
with an ileostomy, apart from the sporadic use of ileorectal
anastomosis. The Kock continent ileostomy was introduced in
the late 1960s, but never achieved universal acceptance,
although the gain in quality of life compared to procto-
colectomywith a conventional stoma seemed clear enough.321
In the past 20 years, the new gold standard has become the
restorative proctocolectomy with ileal pouch-anal anastomo-
sis (IPAA), offering patients an unchanged body image with no
stoma and a preserved anal route of defaecation.322 Never-
theless, bowel function is not restored to normal and both
functional outcome and quality of life after IPAA have still to
be compared to living with an ileostomy.323
This section deals with some aspects on surgery for
ulcerative colitis. IPAA is probably one of the most fre-
quently described procedures in colorectal surgery. There
have been a vast number of publications (498 papers, 58
reviews), but despite this good quality evidence in terms
of randomised studies is scarce (5 on different aspects of
pouch surgery), as is so often the case in surgery. The
indications and timing of surgery for UC are found in the
appropriate sections (acute severe colitis, Section 5.2.4;
refractory colitis, Section 5.2.5; dysplasia or cancer,
Section 9.5).
7.2. Technical considerations
7.2.1. Surgery for acute severe colitis
ECCO Statement 7A
Delay in appropriate surgery is associated with an
increased risk of surgical complication [EL4, RG C]
A staged procedure (colectomy first) is recommended
in the acute case when patients do not respond to
medical therapy [EL 4, RG C], or if a patient has been
taking 20 mg daily or more of prednisolone for more
than 6 weeks [EL 4, RG C]
If the appropriate laparoscopic skills are available, a
minimally invasive approach is feasible and may convey
some advantages [EL4, RG C]
Joint care between senior surgeons and senior gastroen-
terologists remains essential for the safe management of
acute severe colitis. Whilst medical therapy is effective in
many cases there is clear evidence that to delay appropriate
surgery is detrimental to patient outcomes.51 A staged
proctocolectomy (subtotal colectomy first) is considered to
be a wise first step in the surgical treatment of acute severe
colitis or if patients are saturated with steroids. A subtotal
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burden of the colitis, allowing them to regain general health,
normalise nutrition and give the patient time to consider
carefully the option of an IPAA or, perhaps, permanent
ileostomy. A preliminary subtotal colectomy also allows the
pathology to be clarified and Crohn's to be excluded. Subtotal
colectomy is a relatively safe procedure even in the critical ill
patient324–326 and if the appropriate expertise is available,
there is emerging evidence that it is safe to performminimally
invasive or laparoscopic surgery.327,328
7.2.2. Managing the rectal remnant
ECCO Statement 7B
When performing a colectomy for ulcerative colitis in
emergency circumstances, the whole rectum and the
inferior mesenteric artery should be preserved. This
facilitates subsequent pouch surgery [EL 4, RG C].
Whether to preserve additional recto-sigmoid colon
and how to deal with bowel closure is left to the
surgeon's decision [EL 4, RG C]
There are some technical aspects on how to deal with the
rectum when performing an emergency subtotal colectomy.
These might have a bearing on the complication rate and have
implications when the patient comes to a later proctectomy
and IPAA. Leaving as little rectum as possible (i.e. dividing the
middle rectum within the pelvis) is not to be recommended,
because this will render subsequent proctectomy difficult,
with a probable increase in the risk of pelvic nerve injury. The
alternatives are to divide the rectum at the level of the
promontory (i.e. at the proper rectosigmoid junction), or to
leave in addition the distal part of the sigmoid colon. This
allows the bowel to be anchored to the anterior abdominal
wall, facilitating subsequent identification and dissection, or
to bring the bowel up through the abdominal fascia either
closed in the subcutaneous fat, or brought forward as a
mucous fistula. The latter option is considered very safe,
because no closed bowel is left within the abdomen, but the
mucous fistula gives the patient another stoma that is not so
easily managed.329 Closing the stump and leaving it within the
subcutaneous fat are as safe, although the skin is probably
best be left to heal through secondary intention in order to
avoid wound infection.330 There are no studies that give
information on the risk of subsequent inflammation or
bleeding after leaving differing lengths of rectum or
rectosigmoid colon. When the rectum is transected within
the abdominal cavity at the level of the promontory, transanal
rectal drainage is advised for some days, to prevent blow-out
of the rectal stump due to mucous retention.
7.2.3. Site of anastomosis for restorative proctocolectomy
ECCO Statement 7C
When performing pouch surgery, the maximum length
of anorectal mucosa between the dentate line and the
anastomosis should not exceed 2 cm [EL 4, RG C]A common complication of using a stapling technique to
perform the ileo-anal anastomosis is leaving a remnant of
anorectal mucosa above the dentate line. This can be a
cause of persistent inflammation (‘cuffitis’), with pouch
dysfunction and a risk of dysplasia or (very rarely) cancer.331
Careful surgical technique even in the face of a narrow male
pelvis should prevent this from happening. Done well, the
stapled anastomosis seems to have better outcomes,
particularly with regard to soiling, faecal leakage and social
restriction.332,333
7.2.4. Anastomotic technique for restorative
proctocolectomy
ECCO Statement 7D
When performing an IPAA it is mandatory that the
surgical team can also perform a mucosectomy and a
hand-sewn anastomosis should the stapled anastomosis
fail [EL5, RG D]
Nevertheless, the stapling technique occasionally fails, is
impossible, or inappropriate. There is then no room for
re-stapling and the only way of avoiding a permanent stoma
is to hand-sew the anastomosis.
7.2.5. Site of anastomosis for neoplasia complicating colitis
ECCO Statement 7E
When the indication for surgery is cancer or dysplasia
and restorative proctocolectomy is performed, a stapled
anastomosis has equally low rates of subsequent cancer
as hand sewn [EL4, RG C]
The suggestion that a stapled anastomosis leaves mucosa
behind and is thus less safe than doing a mucosectomy and
hand sewn anastomosis in patients who have had cancer or
dysplasia in the resected colon or rectum, does not appear
to be true. The literature reports cancers both in patients
with a stapled anastomosis as well as in those who have had
a mucosectomy, and there is evidence that a mucosectomy
does not necessarily clear all remnants of mucosa.334 In
addition, there is evidence that the stapled technique is as
safe under these circumstances as hand sewn.335 The
number of reported cancers is limited (b30 out of tens of
thousands of IPAA performed worldwide) and is not at
present a cause for alarm.336,337
7.2.6. Role of covering ileostomy for restorative
proctocolectomy
ECCO Statement 7F
When performing a restorative proctocolectomy for
ulcerative colitis a covering loop ileostomy is generally
recommended, but it can be avoided in selected cases
[EL 3b, RG C]
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the complication that is most likely to compromise the
clinical and functional outcome, is a leak in the suture lines
of the anastomosis or pouch. Whether the consequences of a
leak can be ameliorated by a covering ileostomy or not is still
under debate.338,339 However there is emerging evidence
that defunctioning the distal anastomosis may well reduce
the incidence of a leak.340 Nevertheless, in pouch surgery it is
sometimes clear at the time of surgery that the morbidity
associated with a stoma will not justify its use, such as when
there is a thick abdominal wall and a short small bowel
mesentery, as long as there have been no problems constructing
the anastomosis.341–343 Some authors have even attempted to
construct nomograms in an attempt to predict who will benefit
most from defunctioning.3447.2.7. Number of procedures to maintain competency
ECCO Statement 7G
Pouches should be performed in specialist referral
centres. Evidence exists that patients undergoing
pouch surgery in high volume centres do better than
low volume non specialist units. This appears to be the
result of reduced complications and better pouch
salvage in the face of complication [EL 4 RG C]
When performing complex surgical procedures that also
demand sophisticated perioperative care, it has been
shown that institutions performing larger numbers of
operations have better outcomes than those who only
operate on such cases occasionally.345 There is now
evidence to support this view in institutions undertaking
pouch surgery.346 Furthermore, this extends beyond compe-
tence to perform the procedure itself and it is clear that high
volume institutions manage adverse events better and that
this leads to better pouch salvage in the face of complica-
tions.347 It therefore seems logical and appropriate that, if
available, ileoanal pouch surgery should be conducted in high
volume specialist institutions. The numbers required to
establish a ‘specialist high volume unit’ clearly remain for
debate.
7.2.8. Salvage surgery for pouches
ECCO Statement 7H
Salvage surgery for complications of IPAA should only
be done in special centres with adequately skilled staff
and a reasonable number of procedures performed per
annum [EL5, RG D]
Lifetime failure rates for IPAA will probably be in the
region of 15%. Failure implies that the patient has anileostomy for an indefinite period, with or without pouch
excision. Failures are usually due to septic complications or
persistent pouch dysfunction, but sometimes the reason is a
missed diagnosis of Crohn's disease with fistulation, or
refractory pouchitis. Before deciding that a pouch has
failed, the option of salvage surgery either as a corrective
procedure or a complete “redo” has to be considered. The
patient will invariably have a view on this and it should
only be undertaken by colorectal surgeons with special
expertise in this area. Reported series of pouch-rescue
surgery describe a salvage rate above 50% and a still
acceptable functional outcome.348–351 If pouch surgery is
sufficiently complex to recommend a minimum case-load
each year for a unit, it seems appropriate that salvage
surgery, which is even more challenging, should only be
performed in units with a substantial case volume load and
expertise, although it is impossible to quantify a ‘reasonable
number’.
7.3. Follow-up
7.3.1. General pouch follow‐up
ECCO Statement 7I
Follow up should be individualised and focus on those
patients with signs of chronic inflammation in their
mucosa [EL 5, RG D]
General follow-up of people with an IPAA is a matter of
debate. There are no data to suggest that lack of follow-up
incurs any risk for the patient, disregarding the debate on
the risk of cancer. A proportion of patients (perhaps 20–30%)
will develop pouchitis, which may be recurrent or persisting.
These patients will need continuing specialist care, because
primary care physicians or generalists will not have the
expertise necessary for management. The stapled IPAA
where there is a varying length of mucosa below the
anastomosis (see Statement 3C, above), poses an additional
problem since these patients in principle have not had a
curative procedure. However the remaining mucosa repre-
sents a very minute fraction compared to the original colon
and does not represent a clinical problem for most
patients.336
7.3.2. Pouch surveillance
ECCO Statement 7J
There are not enough data to give a general
recommendation on surveillance of pouches with
respect to malignant changes. However, patients
with high risk features, such as: PSC or previous
malignancy or dysplasia should undergo long term
surveillance for pouch or pouch-anal dysplasia [EL5,
RG D]
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mucosa as a result of colonic metaplasia in the pouch has
generated much debate. Approximately 30 pouch cancers
have been reported, almost all in patients operated with
dysplasia or cancer already present in the specimen at
primary surgery. If we are to regularly follow up patients
with IPPAs it would therefore seem sensible to concentrate
on those at highest risk.352–354 The frequency of small bowel
cancers in the background population is very low and the risk
of developing a pouch cancer de novo is likely to be as
uncommon, but remains undefined.355
7.4. Fertility and delivery in patients with a
restorative proctocolectomy
7.4.1. Impact of pelvic surgery on fecundity
ECCO Statement 7K
In a fertile female patient alternative surgical options
such as subtotal colectomy and end ileostomy or
ileorectal anastomosis should be discussed with the
patient, because fecundity is at risk after IPAA [EL3b,
RG B]
It has been convincingly demonstrated in three cohort
studies that female fecundity or fertility is reduced after
IPAA.356–359 The reason for this is most probably adhesions
affecting the fallopian tubes.360 The magnitude of this
problem is under debate, with one study showing N70%
reduction and the others demonstrating around 30% reduced
fecundity. There is however good evidence from a study on
patients with familial adenomatous polyposis, comparing
women with an ileo-rectal anastomosis (IRA) with those with
an IPAA, showing that there is no reduction in fecundity
associated with an IRA.361,362 This appears to be because an
IRA does not induce pelvic adhesions to nearly the same extent
as an IPAA. Furthermore there is evidence that IRA provides a
safe and functionally acceptable outcome.363,364 Not every
woman is a candidate for this approach. Symptoms are less
when there has been a colectomy, since the inflamed colon
has been removed, but the rectum can be expected to remain
inflamed. The persisting risk of rectal malignancy is discussed
in Section 7.5.4. On the other hand, IRA does not disturb
sphincter function, unlike IPAA, does not impair fecundity and
can be discussed as a temporising option.
7.4.2. Mode of delivery for patients with restorative
proctocolectomy
ECCO Statement 7L
There is not enough evidence to recommend a
particular mode of delivery in pregnant women who
have a pouch. Management should be individualised
following an appropriate discussion with the patient,
colorectal surgeon and obstetrician [EL 5, RG D]Vaginal delivery has a 0.5–3.5% risk of inflicting significant
maternal sphincter tears.365,366 The risk is highest at the first
delivery. On the other hand, multiple deliveries have been
shown to prolong pudendal nerve terminal motor latency.367,368
People with an IPAA have a very limited margin for maintaining
faecal continence compared to the general population. This is
because many factors considered important for normal conti-
nence, such as solid stools, rectal sensation, recto-anal nervous
interplay through a recto-anal inhibitory reflex, are absent in
people with an IPAA. Consequently they rely heavily on their
sphincter for maintaining continence. Principally on these
grounds many surgeons recommend that their patient have a
caesarian section rather than a vaginal delivery. However the
literature remains controversial. In both a cohort study and
meta-analysis vaginal delivery appears safe and does not effect
early continence.369–371 Other authors from both Europe and
the US support the recommendation for caesarian deliv-
ery.286,372 More detailed information can be reviewed in the
ECCO Consensus on pregnancy in IBD.373
7.5. Surgical choices in addition to restorative
proctocolectomy
7.5.1. Age
ECCO Statement 7M
Whilst advancing age may lead to poorer outcome, no
defined age limit for performing an IPAA can be
recommended [EL 5, RG D]
Despite the evidence that there are higher levels of
co-morbidity in patients over the age of 65 undergoing IPAA,
the procedure appears safe and effective in this age group.374
However, an increased frequency of long term complications
such as pouchitis or anastomotic stricture in elderly patients
undergoing IPAA has been reported.375 Deterioration in pouch
function with advancing age applies to all patients undergoing
IPAA and faecal incontinence in particular, with evidence that
thismay bemore pronounced in the elderly.376,377 However, it
appears that despite this burden of worsening continence
patients over the age of 65 with IPAA still retain a good quality
of life.378 Decisions about what operation to perform on this
elderly group must therefore be tailored to the individual.
7.5.2. Continent ileostomy
ECCO Statement 7N
The continent ileostomy is still a viable option that can
be used when there is no possibility of performing an
ileal pouch anal anastomosis, or when the IPAA fails for
other reasons than pouchitis, or when the patient
specifically requests this solution [EL 4, RG C]
The continent ileostomy (‘Kock pouch’) was the forerunner to
the IPAA. It is a complex procedure with a high risk of
re-operation. However, well motivated patients with a
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of life with a next-to-normal body image.350,379–382 Furthermore
a failed pelvic pouch can still be converted to a continent
ileostomy which may restore a good quality of life.380,381,383
7.5.3. Ileorectal anastomosis
ECCO Statement 7O
An ileorectal anastomosis should be considered only in
special cases (such as for reasons of fertility). Long term
surveillance of the retained rectum is advised [EL4, RG C]
An ileorectal anastomosis is not only non-curative, but also
leaves patients with the likelihood of persistent symptoms
from refractory rectal inflammation and a risk of later cancer.
Even so, recent series show a better than expected durability,
with half of the patients still living with an IRA after
10 years.364,384,385 Its role in the management of women
facing surgery before they have completed their family is
discussed above (Section 7.4.1). Despite the reduced risk of
subsequent colitis-related dysplasia and malignancy following
colectomy, interval surveillance of the retained rectum is still
recommended.386
7.5.4. Cancer surveillance of the rectal remnant after
colectomy
ECCO Statement 7P
For patients who have a colectomy and ileostomy,
surveillance of the retained rectum is appropriate, which
may be left in situ if the patient so wishes [EL5, RG D]
The literature gives no direct guidance in this matter. The
balance is between the adverse quality of life and cancer risk
of a retained rectal stump and the surgical risks of
proctectomy. Taking out the rectum is a major operation
with a potential for surgical morbidity including delayed
wound healing and risk of sexual dysfunction both in women
and men.387,388 Alternatively, a retained rectum can lead to a
significant reduction in quality of life.389 The issue of cancer
risk in the retained mucosa is also unresolved. Whilst the risk
would seem to be low, reports do exist of interval rectal
cancers and so the recommendation should be that retained
rectal stumps undergo periodic surveillance along the lines of
patients with UC.390,391
7.5.5. Pouch excision after pouch failure
ECCO Statement 7Q
In a patient where the pouch has failed and there is no
hope of re-establishing the anal route of defecation, there
are not enough data to make any recommendation on
whether or not the pouch should be removed [EL5, RG D]Patients whose pouches fail, face a similar dilemma,
balancing these risks and adverse quality of life associated
with a retained pouch with the risk of surgery to remove
failed pouch. The little evidence that exists would suggest
that the quality of life for both retained pouch and those
whose pouches have been removed is similar. However,
men who had their pouches removed were more likely to
suffer from sexual dysfunction. In addition, there were no
dysplastic or malignant changes seen in those patients with
retained pouches at 12 years follow‐up.392,393
7.5.6. Laparoscopic pouch surgery
ECCO Statement 7R
Laparoscopic restorative proctocolectomy with an IPAA
is a technically demanding but feasible operation.
Aside from cosmesis there is no evidence for additional
benefit to the patient [EL 2a, RG B]There is now an abundance of data to suggest that a
laparoscopic approach to IPAA is both feasible and safe. No
randomised trial has yet been published however there are a
number of potential benefit to a laparoscopic approach
including; faster recovery, better cosmesis, reduced burden
of adhesions and thus improved fecundity.394–398.399–403 As
yet the only objective analysis of the data has been a Cochrane
review and the authors' conclusions suggested that there was
to date little advantage in the short andmedium term but that
large, quality randomised trials were needed.404
7.5.7. Pouch surgery for indeterminate colitis, or IBD
yet-to-be classified
ECCO Statement 7S
In indeterminate colitis or colonic IBD yet-to-be classified,
an IPAA can be offered with the information that there
is an increased risk of complications and pouch failure
[EL4, RG C]About 10% of patients with colitis will not have a definitive
diagnosis that discriminates between Crohn's and ulcerative
colitis. Terminology is discussed in Section 1 of this Consensus.
There are reports of less favourable outcomes when
performing pouch surgery for patients with indeterminate
colitis, although others find no significant differences.395,405 In
most series that report outcome after pouch surgery, those
with a secondary diagnosis of Crohn's disease suffer very high
complication and failure rates. Although one group has
reported outcomes equivalent to those with UC for patients
with a pre-operative Crohn's diagnosis, none had pre-operative
small bowel or perianal disease.406 Pouch surgery for patients
with a definitive diagnosis of Crohn's disease cannot be
recommended. For those in whom it is considered an option,
very careful discussion with the patient about increased risks
of sepsis and pouch failure is appropriate.
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7.6.1. Perioperative prednisoloneECCO Statement 7T
Prednisolone 20 mg daily or equivalent for more than six
weeks is a risk factor for surgical complications [EL3b, RG
C]. Therefore, corticosteroids should be weaned if possible
Uncontrolled or retrospective series indicate that patients
taking N20 mg prednisolone for N6 weeks have an increased
risk of surgical complications.110,407–411 Any recommendations
of the rate of steroid reduction after colectomy for acute
severe colitis are arbitrary, but the aim is to avoid acute steroid
withdrawal (‘Addisonian’) crisis, characterised by hypotension,
hyponatraemia and hypoglycaemia in its most severe form.
Milder symptoms may be disguised as a ‘slower than normal’
recovery from surgery. There is little science to steroid
withdrawal and it seems reasonable to reduce the steroid
dose after colectomy immediately to the upper limit of
the daily physiological production of cortisol, which is
about 25 mg. Thus, a daily dose of 25–30 mg cortisol
(hydrocortisone) or of 5–7.5 mg prednisolone seems
appropriate (two thirds of the dose in the morning and
one third in the evening). The rate of further weekly
steroid tapering depends on the dose and duration of
steroids prior to surgery. For patients on steroids for longer
than 6 months, a dose reduction of 1 mg/week over a period of
several months might be advisable.
7.6.2. Perioperative azathioprineECCO Statement 7U
Pre-operative thiopurines do not increase the risk of
postoperative complications [EL3b, RG C]. Colectomy for
ulcerative colitis immediately following or in the medium
term after the use of ciclosporin, appears to have no
higher rate of postoperative complications [EL3b, RG C].
Pre-operative use of infliximab may increase the risk of
post-operative complications [EL2a, RG B]
Azathioprine/mercaptopurine does not appear to increase
the risk of post-operative complications after colectomy.412–414
Whereas several studies do not describe an enhanced
post-operative risk associated with ciclosporin,412,413,51,414,415
the data for tacrolimus are very limited.415
7.6.3. Perioperative infliximab
ECCO Statement 7V
Perioperative use of infliximab does not appear to
increase the risk of infective complications. There may
however be an increase in short term surgical compli-
cations [EL 3a, RG C]TNFα is a critical component of the immune response and its
inhibition by infliximab or other agents could potentially lead
to serious post-operative complications. There are a growing
number of studies investigating the risk of post-operative
complications associated with IFX leading to conflicting results.
A recently published meta-analysis114 included 5 studies with
706 patients.98,110,416–418 The pre-operative use of IFX increased
the total number of short-term (30 days) post-operative
complications (OR 1.80, 95% confidence interval (CI) 1.12–
2.87). However, the subgroup analysis was underpowered to
assess the nature of these complications, but shows a trend
towards increased post-operative infection (OR 2.24, 95% CI
0.63–7.95) whereas non-infectious complications were not
increased (OR 0.85, 95% CI 0.50–1.45). Studies published after
that meta-analysis did not describe an increased rate of
complications after proctocolectomy associated with IFX.419–421
Since nearly all data come from observational studies and not
from randomised controlled trials significant bias may probably
influence the results. In a study from the Mayo Clinic assessing
outcome from IPAA after IFX, anastomotic leaks, pouch-specific
and infectious complications were more common in patients
treated with IFX than in those who did not receive IFX.98,416
After adjustment for concomitant therapy and severity of colitis
IFX was the only factor independently associated with infectious
complications. However, IFX patients were significantly younger
than non-IFX patients, probably reflecting concern that all
medical options were explored before surgery.
The severity of disease and sequential use of ciclosporin can
also influence the post-operative risk associated with preoper-
ative IFX treatment. Patients with less active disease and low
CRP-level, respectively, seem to benefit most from IFX
therapy98,175,303,422 and there is particular concern that emer-
gency colectomy within a few weeks of IFX may be associated
with more septic complications. However, no data are available
that relate only to emergency colectomy for patients with acute
severe ulcerative colitis treated with IFX prior to surgery.
Several studies report efficacy and safety of ciclosporin and
IFX as sequential rescue therapy in patients with steroid-
refractory ulcerative colitis.116,417,423,424 Up to one third of
patients achieved short-term remission and up to two thirds
could avoid short-term colectomy.423,424 These rates appear
similar for patients receiving IFX after failing ciclosporin as
well as for patients receiving ciclosporin after failing IFX.
However, serious adverse events occurred in up to 16% of
patients including sepsis with fatal outcome and herpetic
oesophagitis.116,423 There is no clear evidence if the risk of
infectious complications is dependent on the sequence of the
medications. The short half life of ciclosporin, however, is a
potential advantage compared to IFX if ciclosporin is given
first. Although some of the studies suggest similar complica-
tion rates to those reported with IFX or ciclosporin
alone,423,425 the risk/benefit ratio of sequential rescue
therapy has to be considered carefully in selected patients
only and cannot be recommended routinely due to the high
complication risk. This seems to be especially true if
ciclosporin is given as a second rescue therapy after failing IFX.Acknowledgements
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